{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6n6P0IDA","lastupdate":"2023-10-25T00:00:00.000Z","update_date":"2023-10-25T00:00:00.000Z","lastModified":"Nov 12, 2024","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"mouts-gi","minimal_profile":null,"status":"Public","fullstatus":"Public on NASDAQ on Feb, 2018<br>","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$DrLICg22Ro9VZETHk3GFHLEbfL2EWXgZaBpkxaIizZtW8IIxoHTRTY","name":"Motus GI","oneliner":"Colon Cleansing for Colonoscopy","registrar":"514188135","website":"https://www.motusgi.com","careerspage":"https://www.motusgi.com/about-us/careers","founded_month":10,"founded_year":2008,"formernames":["Booton"],"sociallinks":{"twitter":"https://twitter.com/Motus_GI","youtube":"https://www.youtube.com/channel/UCxoy2H9FLs2FfNQljgR8rHA","facebook":"https://www.facebook.com/MotusGI","linkedin":"https://www.linkedin.com/company/10597881","instagram":""},"social":["https://twitter.com/Motus_GI","https://www.youtube.com/channel/UCxoy2H9FLs2FfNQljgR8rHA","https://www.facebook.com/MotusGI","https://www.linkedin.com/company/10597881"],"flattenedsociallinks":"https://twitter.com/Motus_GI|https://www.youtube.com/channel/UCxoy2H9FLs2FfNQljgR8rHA|https://www.facebook.com/MotusGI|https://www.linkedin.com/company/10597881","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":23,"patent":1,"raised":64500000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Mouts G.I.","Mouts G.I. Medical Technologies","Mouts GI Medical Technologies"],"about":"Motus GI is a medical technology company dedicated to improving endoscopy outcomes and experiences. The company is currently focused on bringing to market the Pure-Vu System, which is designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.\r\n\r\nThe Pure-Vu System has the potential to improve the colonoscopy experience for physicians, patients, and payers by diminishing the dependence on preprocedural preparations, thereby enhancing the quality and cost effectiveness of the exam.\r\n\r\nThe Pure-Vu System is a 510(k) U.S. FDA-cleared medical device indicated for cleaning a poorly prepped colon during the colonoscopy procedure, thus decreasing the dependence on preprocedural prep regimens to achieve a thorough colonoscopy. The device fits over most standard colonoscopes, allowing the physician to clean poorly prepped colons in a safe and effective manner to gain clear visualization of the colon mucosa.\r\n\r\nThe Pure-Vu System has received CE mark approval in Europe and FDA clearance to market Pure-Vu Slim Sleeve, a compatible extension to the Pure-Vu System for slim colonoscopies. In 2020, the company received AMAR approval in Israel and CE mark approval for its Gen2 Pure-Vu System.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97246214447","country":null,"address":{"israeli":[{"id":"aa611abc-09b1-4803-b3c2-2fcd081f00d5","city":"Tirat Carmel","type":null,"address":"Keren HaYesod 22, Tirat Carmel, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"edee44c8-d738-43f7-83e3-b45c62a02631","city":"Fort Lauderdale","address":"1301 E Broward Blvd, Fort Lauderdale, FL, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"North District","news":[{"id":"Q5zMKzIsO91gfdV9Y8Iynaopz7WtwaRifAICwtVvoFoGzX7YyOmza4","date":"May 14, 2024","link":"https://finance.yahoo.com/news/motus-gi-reports-first-quarter-200500092.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Commercial Launch, Financial Results","company":"Motus GI Holdings, Inc.","layoffs":"Not mentioned","summary":"Motus GI Holdings, Inc. has reported its financial results for Q1 2024, revealing a successful limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system. The company has doubled its active customer base and appointed an investment bank to identify strategic alternatives to accelerate the commercialization of the Pure-Vu System. The companys revenue for Q1 2024 was $64,000, compared to $56,000 for the same period last year. The net loss attributable to common shareholders was $7.6 million, compared to a net loss of $4.4 million for the same period last year.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Commercial Launch","Financial Results","Strategic Alternatives","Investment Bank","Stockholder Value"],"date_of_event":"May 14, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners","Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LjorgeuQupofdou0EBmPvrvvM1EsvBSD4XD1emhiBZxOCU9oFqnuNy","news_summary":"Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"61U3kC3QNPK2b1UmwUqWAxSLBedyin0lfUiagDt9qvNUb3DsGataFA","date":"Mar 18, 2024","link":"https://finance.yahoo.com/news/motus-gi-reports-fourth-quarter-200500424.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Partners, Customers","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. has reported its financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update. The company has initiated a limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, and is seeking strategic partnerships to accelerate commercialization of the Pure-Vu System. The company has also received an infusion of $2.7M in gross proceeds from the exercise of certain outstanding warrants, extending its cash runway into the fourth quarter of 2024. The company reported a revenue of $64,000 for the fourth quarter 2023, compared to $109,000 for the same period last year.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Product Launch","Financial Results","Strategic Partnerships","Patent Issuance","Investment"],"date_of_event":"March 18, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$2.7M","structured_issues":["Investment","Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bPgDKZyG4v3pXpZ90eDy31igFC5W9NokmBGK6bEnQTruFjTO5svhIz","news_summary":"Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"p2OoASaXDzHPqISPaY1Sb2cko2WCTP1jgrLn8fbwVSdFmpji8vYyfy","date":"Feb 22, 2024","link":"https://finance.yahoo.com/news/motus-gi-holdings-inc-announces-130000432.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Stock Purchase","company":"Motus GI Holdings, Inc.","layoffs":"Not mentioned","summary":"Motus GI Holdings, Inc. has announced a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor. The exercise will result in the purchase of 2,933,334 shares of the companys common stock, generating gross proceeds of approximately $2.7 million. The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close by February 26, 2024.","partners":"A.G.P./Alliance Global Partners","customers":"Not mentioned","investors":"Institutional Investor","confidence":9,"key_topics":["Stock Purchase","Warrant Exercise","Institutional Investor","Financial Advisor","Working Capital"],"date_of_event":"Feb. 22, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$2.7 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JNto0dmVggajsVOLzaDILaX5Y3rI9juGqkbVqCTeGgMeP6aNG6Ccyd","news_summary":"Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"au88y2aBbao050ryzh6sbJ9g5HQMAQ4g0957tFGzRWR5da10raG6ZD","date":"Feb 21, 2024","link":"https://finance.yahoo.com/news/motus-gi-holdings-granted-u-135200929.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Patent, Medical Technology","company":"Motus GI Holdings, Inc.","layoffs":"Not mentioned","summary":"Motus GI Holdings, Inc., a medical technology company, has been granted a new patent by the United States Patent and Trademark Office (USPTO). The patent, titled Colon Cleaning System with Automatic Self-Purging Feature, covers the automated management of pressure for irrigation and self-purging feature of the latest generation of the Pure-Vu system. The system is designed to improve endoscopic outcomes and experiences. The new patent is expected to further strengthen the companys intellectual property portfolio in the U.S.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["New Patent","Endoscopy","Pure-Vu system","Colon Cleaning","Medical Technology"],"date_of_event":"Feb. 21, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RuXqwi9F9vlQPHmSRv4XogY58n6aPqeJzkRWOR8oWksOqImlqGOjhm","news_summary":"Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8ACjdl5n6B3vxtyjjcv2PRmhRnn3emAxaOQQtIIypHgacQlybpOct6","date":"Feb 16, 2024","link":"https://finance.yahoo.com/news/motus-gi-holdings-inc-announces-211500596.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stockholders Meeting, Voting","company":"Motus GI Holdings, Inc.","layoffs":"N/A","summary":"Motus GI Holdings, Inc. has announced that its special meeting of stockholders, which was held on February 16, 2024, was adjourned without conducting any business. The meeting was adjourned to provide stockholders additional time to vote on a proposal described in the companys definitive proxy statement. The adjourned meeting will reconvene on March 7, 2024. The companys board of directors believes that the stockholders approval of the proposal is in the best interests of the company and its stockholders.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Stockholders Meeting","Voting","Adjournment","Proxy Statement","Proposal"],"date_of_event":"February 16, 2024","valuation_amount":"N/A","impact_on_company":"Neutral","investment_amount":"N/A","structured_issues":"Management Changes","acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"ZTz4bTGLqYMdiMI5kAOfQwxm0qgBsG0PfSaagY5iWR5gFoBKKUbBuU","news_summary":"Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"i1QWk1c0Cmmk6zGpFccNWTbK2BN89YXnhwfVXtJ5ThyeohZjp6pPzM","date":"Feb 6, 2024","link":"https://finance.yahoo.com/news/zacks-com-featured-highlights-lancaster-085900062.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stocks, Investment","company":"Lancaster Colony, On Holding, Rent the Runway, 5E Advanced Materials, Motus GI","layoffs":"Not mentioned","summary":"The article discusses the potential for strong returns from stocks with a rising price-to-earnings (P/E) ratio. It suggests that investors can bet on companies like Lancaster Colony, On Holding, Rent the Runway, 5E Advanced Materials and Motus GI, as their rising P/E indicates inherent strength and potential for growth. The article explains that as earnings rise, so should the price of the stock, and a rising P/E ratio suggests that investors are willing to pay more per dollar of earnings, expecting the companys earnings to rise at a faster pace in the future.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":"P/E Ratio, Stock Value, Earnings Growth, Investment Strategy, Market Forecast","date_of_event":"February 6, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"789XmD7IfmreTQwuDZPdGpvXYWtoMB2KHxq3m8gPZRZpiGdBjkzQ8o","news_summary":"Zacks.com featured highlights Lancaster Colony, On Holding, Rent the Runway, 5E Advanced Materials and Motus GI","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9EOXPh4cIjQNqnuq9a14K5GYPFrErfWHctrJQU4WCzjfCYcOnPSWaj","date":"Jan 30, 2024","link":"https://finance.yahoo.com/news/motus-gi-holdings-publishes-positive-130000829.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Medical Technology, Endoscopy","company":"Motus GI Holdings, Inc.","layoffs":"N/A","summary":"Motus GI Holdings, Inc. has announced the publication of positive data from a study of the second generation Pure-Vu System. The study concluded that adequate bowel cleaning can be achieved in patients with a history of inadequate bowel preparation by using the Pure-Vu System. This would reduce the number of repeat colonoscopies and clinical admissions for bowel preparation. The company has also secured FDA clearance for its next generation system, which features key enhancements.","partners":"N/A","customers":"Patients with history of inadequate bowel preparation","investors":"N/A","confidence":9,"key_topics":["Pure-Vu System","Bowel Cleansing","Clinical Study","Positive Results","FDA Approval"],"date_of_event":"Jan. 30, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers","acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KVwLYsgQT1f31Uwa2vdpCO8lnE16o7NYjKVstBlFiSd7sqQrFfHa1x","news_summary":"Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gOq2Pel7VlVJ29VIBxgbyrp8pDcap3BCt60lQd0eUslMezXLlC4RxZ","date":"Jan 7, 2024","link":"https://finance.yahoo.com/news/reasons-feel-uneasy-motus-holdings-085659946.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Financial Performance","company":"Motus Holdings","layoffs":"Not mentioned","summary":"Motus Holdings has shown a decrease in its return on capital employed (ROCE) from 26% five years ago to 17% currently. However, the companys capital employed and revenue have both increased, indicating that the business is pursuing growth despite short-term returns. The company has also decreased its current liabilities to 49% of total assets, reducing some elements of risk. Despite lower returns in the short term, Motus Holdings is reinvesting for growth and has higher sales as a result. The companys stock has delivered a 32% gain to shareholders whove held over the last five years.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["ROCE","Investment","Growth","Financial Performance","Risk"],"date_of_event":"January 7th 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IUzcjrQoJjgd8JUWnaARlfgwhd0zdsY3pM4zBuTP5bHDuHiAVYrn7A","news_summary":"There Are Reasons To Feel Uneasy About Motus Holdings' (JSE:MTH) Returns On Capital","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9JQeWPKNz4h3poNg906nW3uyyWdh8Xwdg2IYw93x0l66UGyVuLJSJS","date":"Dec 21, 2023","link":"https://finance.yahoo.com/news/investors-motus-holdings-jse-mth-123657221.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance","company":"Motus Holdings Limited","layoffs":"Not mentioned","summary":"The share price of Motus Holdings Limited has increased by 66% in the last three years, outperforming the market return of around 16%. The companys earnings per share (EPS) grew at 127% per year over three years, which is higher than the 18% average annual increase in the share price. The total shareholder return (TSR) over the last 3 years was 101%, which is better than the share price return. However, investors in Motus Holdings had a tough year, with a total loss of 8.3% (including dividends), against a market gain of about 3.2%.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Stock Performance","Earnings Per Share","Dividends","Total Shareholder Return","Market Returns"],"date_of_event":"December 21st 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kicYxWvARSSqSN458XgPrKvqZkxLd7ibzSmVWNyvrfFhEAuDpBwBON","news_summary":"Investors in Motus Holdings (JSE:MTH) have seen splendid returns of 101% over the past three years","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"reWd3GFMdbTe8rRWwQIrFRaAivN7lS35ay28JmBb5uIPZoXBHz9pRB","date":"Dec 19, 2023","link":"https://finance.yahoo.com/news/motus-gi-holdings-inc-announces-031000750.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Public Trading, Investment","company":"Motus GI Holdings, Inc.","layoffs":"Not specified","summary":"Motus GI Holdings, Inc., a medical technology company, has announced the pricing of a public offering of over 3 million shares of common stock and Series A and B common warrants. The combined public offering price is $1.50 per share and each warrant, with aggregate gross proceeds expected to be approximately $5.0 million. The offering is expected to close on December 21, 2023, subject to customary closing conditions. The company plans to use the net proceeds for working capital and other general corporate purposes.","partners":"A.G.P./Alliance Global Partners","customers":"Not specified","investors":"Not specified","confidence":9,"key_topics":["Public Offering","Medical Technology","Endoscopy Solutions","Stock Warrants","Investment"],"date_of_event":"Dec. 18, 2023","valuation_amount":"Not specified","impact_on_company":"growth-positive","investment_amount":"$5.0 million","structured_issues":["Investment","Public Trading"],"acquisition_amount":"Not specified","structuredIssuesShow":"#Investment  #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"e4RZcjQa914LHTCthdltASRaTObvmY7bJs6fh8zxkL6D88pS7uaKwA","news_summary":"Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"F2GeP6bAdahoeDxKJ5vQ0uirPEJbro4yOo7lC2Bb7AJxEmObYfkbCR","date":"Dec 5, 2023","link":"https://finance.yahoo.com/news/did-motus-holdings-limited-jse-043036848.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment Analysis","company":"Motus Holdings Limited","layoffs":"Not mentioned","summary":"The article discusses the use of Return On Equity (ROE) as a tool to understand a business, using Motus Holdings Limited as an example. ROE is used to assess the profitability of a company in relation to its equity capital. The ROE for Motus Holdings is 19%, which is close to the average for the Specialty Retail industry. However, the companys high use of debt, leading to a debt to equity ratio of 1.51, is noted as a potential risk. The article concludes that while ROE is a useful tool, it is just one piece of a larger puzzle in assessing a companys quality and potential for growth.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Return On Equity, Debt Impact, Profitability, Equity Capital, Industry Comparison","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"WafLTh1m6Cis2JQyk6uE7lloW9cDqOOVuvILyWmMtCcSQao180lBd0","news_summary":"Did Motus Holdings Limited (JSE:MTH) Use Debt To Deliver Its ROE Of 19%?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"VuQnyfYxbTc7iZbRkDwPfmrbc95K61paIp2ZPSx75D4egma5uO6R1R","date":"Nov 19, 2023","link":"https://finance.yahoo.com/news/r102-motus-holdings-limited-jse-083508446.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Market, Investment","company":"Motus Holdings Limited","layoffs":"Not mentioned","summary":"Motus Holdings Limited has seen a double-digit share price rise of over 10% in the past couple of months on the JSE. The companys outlook and value based on the most recent financial data suggest that it is fairly priced at around 20% below its intrinsic value. The companys earnings growth is expected to be in the teens in the upcoming years, indicating a solid future. However, the market has already priced in the companys positive outlook, with shares trading around its fair value.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Share Price","Investment","Growth","Valuation","Market Volatility"],"date_of_event":"Not mentioned","valuation_amount":"20% below intrinsic value","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"74bqTmkXPSWeL8Q3Ynpe4Ok2re6sLABSYtyL6BSpfz21S3A8z3IFlN","news_summary":"At R102, Is Motus Holdings Limited (JSE:MTH) Worth Looking At Closely?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Wc8EUF44ZO3RBx2utPYwLyLhFx2UHMxkzKdTz9csBglV7y3BUW7PGY","date":"Nov 13, 2023","link":"https://finance.yahoo.com/news/motus-gi-reports-third-quarter-210500461.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA clearance","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc., a medical technology company, announced the FDA clearance of its Pure-Vu® EVS Gastro system, targeting the upper GI market. The company plans to introduce the system to top U.S. hospital systems by the end of 2023. Motus GI is also exploring strategic and financing alternatives to accelerate commercialization and maximize stockholder value. The company received approval from the Israeli Ministry of Health for commercial sales in Israel and is finalizing the CE Mark process in Europe. Additionally, Scott Durbin was appointed to the Board of Directors. These developments are expected to enhance the companys market position and growth prospects.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["FDA clearance","GI market","strategic alternatives","commercialization","stockholder value"],"date_of_event":"November 13, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"wtUzD0nR8WNPkwfTiJLXSFYogIdskeNa0kAuPZvWgXJGSGElsiave0","news_summary":"Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Hm935qn6sN7PO8lEpJAlb5mKiGqxeaR4ifWCJsg4O1wkOSjP41Nrq8","date":"Nov 13, 2023","link":"https://finance.yahoo.com/news/motus-gi-reports-third-quarter-210500461.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, FDA Clearance","company":"Motus GI Holdings, Inc.","layoffs":"N/A","summary":"Motus GI Holdings, Inc. has reported its financial results for Q3 2023, revealing a revenue of $86,000, compared to $278,000 for the same period last year. The company has also announced the successful first case performed using the new FDA cleared Pure-Vu® EVS Gastro system, with broader market introductions expected by the end of 2023. The company is also exploring strategic and financing alternatives to accelerate the commercialization of the Pure-Vu System. Additionally, the company has appointed Scott Durbin to its Board of Directors.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["FDA Clearance","Financial Results","New Product","Strategic Alternatives","Management Changes"],"date_of_event":"Nov. 13, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment","Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9WnWo4mjwzrPjQ4BvLBMI6nt3PyYgdFv5QytfJ2ggw6JL9HjgTzC6Z","news_summary":"Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"MZtS1VJwObNJoTCRhZ34EhchFl7eBk5siIxCcPI8jxQKKgwnlpflTU","date":"Nov 10, 2023","link":"https://finance.yahoo.com/news/motus-gi-announces-first-upper-130000072.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Medical Technology, FDA Clearance","company":"Motus GI Holdings, Inc.","layoffs":"N/A","summary":"Motus GI Holdings, Inc., a medical technology company, has announced the successful use of its Pure-Vu® EVS Gastro in the first procedure since receiving FDA clearance. The procedure was performed by Dr. Brian Hanson at the University of Minnesota. The Pure-Vu® EVS Gastro addresses the Upper GI market, a high unmet clinical need, including approximately 400,000 cases of upper GI bleeds per year in the U.S. The company is working to place this new device and their next generation colon product in top hospital systems to establish a foundation of reference centers.","partners":"N/A","customers":"University of Minnesota","investors":"N/A","confidence":9,"key_topics":["FDA Clearance","Upper GI Procedure","Pure-Vu EVS Gastro","Market Introduction","Clinical Need"],"date_of_event":"Nov. 10, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HwrovjfrjjgJKCGgjLc5fISlMolPsTHmYZWF1TkG2MrUKamzNlL07V","news_summary":"Motus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu® EVS Gastro","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"qepNkyPr14t88P87msDzAmi1YgKdSbPx0KFAwpYN9klWVWJBlBB743","date":"Nov 2, 2023","link":"https://finance.yahoo.com/news/look-why-motus-holdings-limiteds-040356782.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"CEO Compensation, Company Performance","company":"Motus Holdings Limited","layoffs":"N/A","summary":"Motus Holdings Limited is set to hold its Annual General Meeting on November 8th, where CEO Osman Arbees compensation will be discussed. Arbees total pay includes an R11.3m salary, with total compensation reported as R28m for the year to June 2023, a decrease of 41% from the previous year. This is in line with the median for CEOs in the South African Specialty Retail industry. The company has seen significant growth, with EPS growing by 127% over the past three years and a total shareholder return of 160% over the same period.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":"10","key_topics":"CEO Compensation, Company Performance, Annual General Meeting, Shareholder Return, Revenue Growth","date_of_event":"8th of November","valuation_amount":"R16b","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Management Changes","acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Wdj4Uf6ku7fIJqs4YNbwnCOL1aAVFxME1Y71iIb8OHhjleeM4CmJgo","news_summary":"We Take A Look At Why Motus Holdings Limited's (JSE:MTH) CEO Has Earned Their Pay Packet","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"GXj0shcyEevOgq1DWHgtlhHak7F2UfPi3PhJnJZmFQASUyNkTgOFdr","date":"Nov 1, 2023","link":"https://finance.yahoo.com/news/motus-gi-announces-1-15-120000658.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Public Trading, Management Changes","company":"Motus GI Holdings, Inc.","layoffs":"N/A","summary":"Motus GI Holdings, Inc. has announced a 1-for-15 reverse stock split of its outstanding common stock to increase the per share trading price and satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 8.7 million to approximately 0.6 million. The reverse split will not alter any stockholder’s percentage interest in the Company’s equity, except for the issuance of fractional shares. The board of directors approved the reverse stock split at a ratio of 1-for-15 on October 27, 2023.","partners":"Continental Stock Transfer & Trust Company","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Reverse Stock Split","Nasdaq Listing","Stockholder Impact","Share Reduction","Board Approval"],"date_of_event":"November 1, 2023","valuation_amount":"N/A","impact_on_company":"Neutral","investment_amount":"N/A","structured_issues":["Public Trading","Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading  #Management Changes","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"R5RJqARonQ0aPXRlP5QG2WKlruk5dCK3ciA2BptPuaaVtweXzLAl82","news_summary":"Motus GI Announces 1-for-15 Reverse Stock Split","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"kZgDUKjrgptzHbWbj9zeRgJBCfFHf2BR1XPawj2MGt2FGpmmzfIWLx","date":"Oct 24, 2023","link":"https://finance.yahoo.com/news/motus-gi-receives-fda-clearance-120000408.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA clearance, technological advancements","company":"Motus GI Holdings, Inc.","layoffs":"Not mentioned","summary":"Motus GI Holdings, Inc., a medical technology company, has received FDA clearance for its new Pure-Vu EVS Gastro and Gen 4 Colon system. The new system features technological advancements that improve the performance, ease of use, and reduces the need for onsite support. The Pure-Vu EVS Gastro opens the upper gastrointestinal (GI) market and provides access to high acuity patients suffering from upper GI bleed. The company plans to initiate the market introduction of the new platform by the end of the year.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["FDA clearance","Technological advancements","Upper GI market","Pure-Vu EVS platform","Market introduction"],"date_of_event":"Oct. 24, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Customers, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"h2cE4QKfQ5dgQpuBAyEehpVmWkWpKTcWpfBYgw5JTblWd2HoG4mffN","news_summary":"Motus GI Receives FDA Clearance to Commercialize Pure-Vu EVS Gastro and Gen 4 Colon","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9dGRZ8kckWBcikA9g2VxMP76jsRc46i3X3OlpX3TFUmFuH0YBmtPDS","date":"Oct 23, 2023","link":"https://finance.yahoo.com/news/52-ownership-shares-motus-holdings-103528165.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Institutional Ownership, Shareholder Influence","company":"Motus Holdings Limited","layoffs":"Not mentioned","summary":"Institutions own 52% of Motus Holdings Limited, giving them significant influence over the company. The top 5 shareholders control over half of the company, indicating their sway over decision-making. The largest shareholder is Public Investment Corporation Limited with 14% of shares, followed by Coronation Fund Managers Limited and Ukhamba Holdings (Proprietary) Limited with 12% and 11% respectively. Insiders own R803m worth of stock in the R16b company. The general public owns 13% of the company, while private companies own 15%.","partners":"Not mentioned","customers":"Not mentioned","investors":"Public Investment Corporation Limited, Coronation Fund Managers Limited, Ukhamba Holdings (Proprietary) Limited","confidence":9,"key_topics":"Institutional Ownership, Shareholder Influence, Insider Selling, Public Ownership, Private Company Ownership","date_of_event":"Not mentioned","valuation_amount":"R16b","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"dLekqPXpCmLT8rCdK66yB1fvEj4qZtIswkwSxEpyT21QwUh73hnheg","news_summary":"With 52% ownership of the shares, Motus Holdings Limited (JSE:MTH) is heavily dominated by institutional owners","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Ibcop4CCntRKyGEh7x3X7sUllCWMKM0jlJw59Um4AjfpskAIQtN7Q8","date":"Sep 26, 2023","link":"https://finance.yahoo.com/news/motus-gi-submits-special-510-120000190.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Medical Technology, FDA Approval","company":"Motus GI Holdings, Inc.","layoffs":"Not mentioned","summary":"Motus GI Holdings, Inc., a medical technology company, has submitted a special 510(k) to the U.S. Food and Drug Administration (FDA) for market clearance of its Pure-Vu Gen 4 Gastro and Colon. The new platform is designed to improve endoscopic outcomes and experiences, and is expected to reduce the cost of goods by approximately 50%. The company believes that the new platform will open up the Upper GI market and minimize the need for onsite support to new accounts. The submission is supported by positive preclinical and clinical data collected by key opinion leaders in the U.S. and abroad.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["FDA Approval","Medical Technology","Product Launch","Market Expansion","Cost Reduction"],"date_of_event":"Sept. 26, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NZIsPiHRcv7wgxhQ5piBACLevAZSvNl8YL5TbxVC8rnQywOihRv1fs","news_summary":"Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"q7ygRHl0WKMA5mtN7dWnXXjdyv49YzCKsTSQDEggWJLIISt6TcMHGG","date":"Sep 14, 2023","link":"https://finance.yahoo.com/news/motus-gi-amends-royalty-agreement-200500841.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"royalty elimination","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc., a medical technology company, announced an amended agreement to eliminate approximately $1 million in contingent royalty obligations from its balance sheet. The royalty rights were canceled in exchange for 1,455,641 shares of common stock. This move is expected to improve the companys stockholder equity and simplify its exploration of strategic and financing alternatives. Additionally, the company plans to submit a special 510(k) to the FDA by early Q4 2023 for the next generation of its Pure-Vu EVS system, aiming to expand its capabilities into supporting upper GI procedures.","partners":null,"customers":null,"investors":[],"confidence":10,"key_topics":["royalty","stock","equity","FDA","Pure-Vu"],"date_of_event":"September 12, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qMOijkEf6fYDiw5dlx0j9M2faU69Zu0gHqLzd7VEU0jBbQbK7yj4pX","news_summary":"Motus GI Amends Royalty Agreement","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"UoVAFlcF94m9sVwACsWIzTN73fBNnGEKoSML4O6TMpRQsRIegAQ2ec","date":"Sep 6, 2023","link":"https://finance.yahoo.com/news/motus-gi-appoints-medical-device-210000067.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Changes","company":"Motus GI Holdings, Inc.","layoffs":"N/A","summary":"Motus GI Holdings, Inc. has announced the appointment of Scott Durbin to the Company’s Board of Directors. Durbin brings over 25 years of executive leadership, finance and clinical development experience. The company also announced the resignation of David Hochman and Darren Sherman from the Board, due to their executive obligations at Orchestra BioMed Holdings, Inc. Durbins appointment is expected to bring value to Motus and complement the experience of the current Board. The company is looking forward to securing FDA clearance for its next generation system and accelerating the commercialization of the Pure-Vu System.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Board Resignation","Board Appointment","FDA Clearance","Pure-Vu System","Commercialization"],"date_of_event":"Sept. 06, 2023","valuation_amount":"N/A","impact_on_company":"Neutral","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"zFVm8w0zPo2TCfi2mifbV6GlazwImKDJ8ssfBathnk68PP9UfUs7UU","news_summary":"Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"HO70RGzEn9dgw0TPHhY4f6cZrWYhdLC9CzoTnWhaCmroUcgl7zPAQb","date":"Sep 1, 2023","link":"https://finance.yahoo.com/news/motus-holdings-full-2023-earnings-040056503.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial results","company":"Motus Holdings","layoffs":null,"summary":"Motus Holdings has released its Full Year 2023 Results, showing a 16% increase in revenue compared to the previous year. Net income also saw a 1.9% increase. However, the profit margin decreased from 3.6% to 3.2% due to higher expenses. Earnings per share (EPS) increased from R19.02 to R20.08. The companys performance is in line with analyst expectations, and revenue is forecasted to grow 9.1% annually over the next 2 years. The stock may be undervalued based on various valuation benchmarks. The article provides general commentary and does not constitute financial advice.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Revenue","Net income","Profit margin","EPS","Valuation"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"eksYTwpGelxdpMpcmsp6L5TiRekpAphIoSQ0WjTTjqGVhaPoSAZpiv","news_summary":"Motus Holdings Full Year 2023 Earnings: In Line With Expectations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"RGsBsvErVzii7cBkJrMnqVPiE80VE3bYr15Wv1FrsPe2ss6vfywhhz","date":"Aug 24, 2023","link":"https://finance.yahoo.com/news/motus-gi-present-h-c-200500809.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"presentation","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. announced that its President and CEO will present at the H.C. Wainwright 25th Annual Global Investment Conference. The webcast of the presentation will be available on the companys website for 90 days.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["presentation","medical technology","endoscopic outcomes","H.C. Wainwright 25th Annual Global Investment Conference","webcast"],"date_of_event":"August 24, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oiZo9POXqFofDRbstzbaWWhCWqCsmJhyig4FooK9uORPhy1gmHdMTt","news_summary":"Motus GI to Present at the H.C. Wainwright 25th Annual Global Investment Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"HNTK7rEKdzd5xexOwZNtJhSZjPK2GrI8dvbtBW9C3bvEwbCu6ziONE","date":"Aug 14, 2023","link":"https://finance.yahoo.com/news/motus-gi-reports-second-quarter-200100166.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Product Development","company":"Motus GI Holdings, Inc.","layoffs":"Not specified","summary":"Motus GI Holdings, Inc. reported its financial results for Q2 2023, with a revenue of $113,000 compared to $185,000 for the same period last year. The company is on track to submit a special 510(k) for Pure-Vu Gen 4 Gastro and Colon to the FDA in Q4 2023. It also received system-wide approval in the Banner Medical Hospital Network. The company has completed two rounds of cost-cutting measures in 2023, reducing operating expense cash burn by more than 50%. The cuts are mainly due to reductions in the company’s executive management, workforce, and clinical expenses.","partners":"Banner Medical Hospital Network, Israeli Ministry of Health, Medical Device Division","customers":"Banner Medical Hospital Network","investors":"Kreos Capital","confidence":9,"key_topics":["Financial Results","Product Development","Cost-cutting Measures","Regulatory Approval","Partnerships"],"date_of_event":"Aug. 14, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Management Changes","Layoffs"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Management Changes  #Layoffs","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nSfdBDoMwnjSEsZ7ctrlXy2FjuA8xck5alps5UknpsBNhVQs2y2o0f","news_summary":"Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"P8ENSC1g3F3TJ8XvKwBtHgtbiwhtsmXL7S6AhCw6XQujN0XQWYlSej","date":"Aug 10, 2023","link":"https://finance.yahoo.com/news/motus-gi-receives-approval-israeli-130000431.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Regulatory Approval, Market Expansion","company":"Motus GI Holdings, Inc.","layoffs":"N/A","summary":"Motus GI Holdings, Inc., a medical technology company, has received approval from the Israeli Ministry of Health to initiate commercial sales of the Pure-Vu® EVS System in Israel. The Pure-Vu System EVS is designed to improve visualization during colonoscopy and endoscopy, particularly for patients who are elderly, with comorbidities, or active bleeds. The system is already cleared by the U.S. Food and Drug Administration (FDA). The approval supports the companys strategy to enable strategic partnerships with medical device companies on a global basis.","partners":"N/A","customers":"Israeli Ministry of Health, Medical Device Division","investors":"N/A","confidence":9,"key_topics":["Regulatory Approval","Pure-Vu EVS System","Market Expansion","Medical Technology","Endoscopy"],"date_of_event":"Aug. 10, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SrpwRZiTYlxl7NHuUHOuM5IRxAiRq9XQDiTy5vFPncetfMQKqpPwGS","news_summary":"Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b4uDZGM5qZIUGk3GMvFgX6lbLXcaIJxJgzy65IhjFvanPDRZancrlv","date":"Jul 26, 2023","link":"https://finance.yahoo.com/news/motus-holdings-jse-mth-reinvesting-092406981.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance","company":"Motus Holdings","layoffs":null,"summary":"Motus Holdings return on capital employed (ROCE) is not showing a promising trend, having fallen from 25% five years ago to 19% currently. However, the companys revenue and the amount of assets employed in the business have increased, suggesting that the company is investing in growth. The company has also decreased its current liabilities to 48% of total assets, which could partly explain why the ROCE has dropped. Despite the falling returns, the stock has returned a huge 293% to shareholders in the last three years.","partners":[],"customers":[],"investors":[],"confidence":8,"key_topics":["ROCE","Capital Employed","Revenue Growth","Investment","Stock Returns"],"date_of_event":"Not specified","valuation_amount":null,"impact_on_company":"Neutral","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"hkNiUfMj4E56hH64ZQ0oY6XrbXL7zBiItnAAi7GW9MybT8pk0Uk02f","news_summary":"Motus Holdings (JSE:MTH) Is Reinvesting At Lower Rates Of Return","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"h9VCrvVOxUUPAaJIlMkz4eMAmZVfn75HarHcz6GD9qnsFqUmMIjdgo","date":"Jul 20, 2023","link":"https://finance.yahoo.com/news/motus-gi-announces-purchase-agreement-120000427.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Medical Technology, Endoscopy","company":"Motus GI Holdings, Inc.","layoffs":"N/A","summary":"Motus GI Holdings, Inc. has announced that Banner Desert Medical Center has purchased and begun implementing the Pure-Vu System, designed to improve endoscopic outcomes. The system is expected to enhance the efficiency and clinical outcomes of inpatient colonoscopy procedures. This partnership is expected to facilitate an easier sales process to other medical centers within the Banner Medical network. The Pure-Vu System integrates with standard and slim colonoscopes to improve visualization during colonoscopy while preserving established procedural workflow and techniques.","partners":"Banner Desert Medical Center","customers":"Banner Desert Medical Center","investors":"N/A","confidence":9,"key_topics":["Pure-Vu System","Endoscopy","Medical Technology","Partnership","Expansion"],"date_of_event":"July 20, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Partners","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YGcURSVyjtTLlLMH85tBb1tW4XPDZganhDvLsRpWVNuQ5GTALCftER","news_summary":"Motus GI Announces Purchase Agreement for the Pure-Vu System® from Banner Desert Medical Center","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"y9MpnTCRqVBn0HUju6yrXIOBCympGOLdeUNHirYwZaIUFyIbFxhq0U","date":"Jul 13, 2023","link":"https://finance.yahoo.com/news/motus-gi-holdings-inc-mots-160006996.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Upgrade, Earnings Estimates","company":"Motus GI Holdings, Inc.","layoffs":"Not Mentioned","summary":"Motus GI Holdings, Inc. has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting an upward trend in earnings estimates. The Zacks rating system tracks the consensus measure of EPS estimates from sell-side analysts covering the stock for the current and following years. The upgrade for Motus GI Holdings is a positive comment on its earnings outlook, which could positively impact its stock price. For the fiscal year ending December 2023, the company is expected to earn -$2.12 per share, a change of 63.1% from the year-ago reported number. Over the past three months, the Zacks Consensus Estimate for the company has increased 36.8%.","partners":"Not Mentioned","customers":"Not Mentioned","investors":[],"confidence":9,"key_topics":["Stock Upgrade","Earnings Estimates","Investment Research","Zacks Rank","Stock Price"],"date_of_event":"Not Mentioned","valuation_amount":"Not Mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not Mentioned","structured_issues":[],"acquisition_amount":"Not Mentioned","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"7K867u0hoAy4aKT1z3x2YhSy3e36oPnLVGSwwfM8CDIRhux8XIOnR4","news_summary":"Motus GI Holdings, Inc. (MOTS) Upgraded to Strong Buy: Here's What You Should Know","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"IsvgxvysPUG1CyOsTVzaficiuXUt0SGa3w1xFAOJNxJz5Cu7oZWTOi","date":"Jul 12, 2023","link":"https://finance.yahoo.com/news/lacklustre-performance-driving-motus-holdings-085948021.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance","company":"Motus Holdings Limited","layoffs":"N/A","summary":"Motus Holdings Limiteds price-to-earnings (P/E) ratio of 5x may indicate bullish signals, as nearly half of all companies in South Africa have P/E ratios greater than 9x. Motus Holdings has shown superior earnings growth compared to most other companies, which could be a reason for the reduced P/E. However, estimates suggest that the companys earnings should grow by 6.3% per annum over the next three years, which is less than the markets forecasted expansion of 11% per year. This could be why Motus Holdings is trading at a P/E lower than the market.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Price-to-Earnings Ratio","Earnings Growth","Future Projections","Share Price","Market Forecast"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Investment","acquisition_amount":"N/A","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"azp1y5LLAxmOlPHvpufbBgMXJ07nkxOhTJo3Bvg6F7dM0j7i2WBCAM","news_summary":"Lacklustre Performance Is Driving Motus Holdings Limited's (JSE:MTH) Low P/E","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"UlnKoDyJcsi5FehDuRadxbLje0ly6UUWeWFJLcvDa0SitHTJGhyfO8","date":"Jun 28, 2023","link":"https://finance.yahoo.com/news/eps-growth-important-motus-holdings-064313879.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"SOI7qczMFhKOuxAtemrwIsLaG5iQh57d76phGw3VhoWszcqF8tlJZV","news_summary":"If EPS Growth Is Important To You, Motus Holdings (JSE:MTH) Presents An Opportunity","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"3MqC0DG3N0f4dpU14a07BT2fjCe60JGdyiPhLEXfUfVbcqbantqm8J","date":"Jun 14, 2023","link":"https://finance.yahoo.com/news/boasting-23-return-equity-motus-042442514.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Return On Equity","company":"Motus Holdings Limited","layoffs":null,"summary":"The article discusses the importance of Return On Equity (ROE) and analyzes the ROE of Motus Holdings Limited. It states that Motus Holdings has a superior ROE compared to the industry average, indicating good profitability. However, it also highlights the high debt-to-equity ratio of the company, which could pose risks. The article suggests that a company with a high ROE and low debt could be considered a high-quality business. It advises investors to consider various factors, including profit growth rates and stock price expectations, when determining the right price to buy a stock. The article concludes by stating that the analysis is based on historical data and analyst forecasts and should not be considered as financial advice.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Return On Equity","Debt","Profitability","Stock Price","Business Quality"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cpVxSlNW0Bi3WcHfMYc4wuqNZNVe93UnuvzC8dfqbQdvVq6NJOghQc","news_summary":"Boasting A 23% Return On Equity, Is Motus Holdings Limited (JSE:MTH) A Top Quality Stock?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Qh8YfJ63xjuYc3EFqI2A8jxMm94UWWsmLd1nKbOBLOLWsNgQ8iCp4D","date":"Jun 14, 2023","link":"https://finance.yahoo.com/news/motus-gi-announces-pure-vu-120000166.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"medical technology","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. announced that its Pure-Vu Gen 4 Gastro and Colon system was featured during the 9th Ecuadorian Institute of Digestive Diseases (IECED) Live Endoscopy Course 2023. The system was used to support an underwater endoscopic mucosal resection (UEMR) during a live case conducted by Dr. Carlos Robles-Medranda. The Pure-Vu Gen 4 Gastro was also featured in a hands-on demonstration area. The company received positive feedback and plans to submit a 510(k) application to the U.S. FDA for the Pure-Vu Gastro device in Q4 2023. The Pure-Vu Gen 4 Gastro and Colon systems utilize the same workstation and aim to improve visualization in both the upper and lower GI tract. Motus GI is a medical technology company focused on improving endoscopic outcomes and experiences.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Pure-Vu system","Live Endoscopy Course","FDA submission","Gastro and Colon system","brand awareness"],"date_of_event":"June 14, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iBgc1qYuurNZ5J5zbx8G0DUUdrE2F6loVYptwImGILAiHpReQcOcO8","news_summary":"Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 at the Pentax Learning Center","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Lj4zECumRgKoYvlbdEvNn8zLTNdTzHk0VipI3C43rx2cOFqHfdjevc","date":"Jun 7, 2023","link":"https://finance.yahoo.com/news/orchestra-biomed-appoints-bill-little-123000400.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"executive appointments","company":"Orchestra BioMed Holdings, Inc.","layoffs":null,"summary":"Orchestra BioMed has appointed Bill Little as EVP of Corporate Development and Strategy and Andrew Taylor as CFO. The companys business model focuses on risk-reward sharing partnerships to advance innovative medical technologies to market. Littles appointment marks the establishment of a formal corporate development function within the company, while Taylor brings over 20 years of CFO experience in the medical device sector. The company aims to generate additional value for stakeholders through their leadership. Orchestra BioMed has strategic collaborations with Medtronic and Terumo Corporation for the development and commercialization of their flagship product candidates. The company plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing, and organic development.","partners":["Medtronic","Terumo Corporation"],"customers":null,"investors":null,"confidence":9,"key_topics":["Executive Appointments","Corporate Development","Partnerships","Medical Device Sector","Business Model"],"date_of_event":"2023-06-07","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zG3nZjy3SJ3Hv4Y2WGH9NSlhAwThY8MNDQTi8EiGOExFDwzR5GlKWI","news_summary":"Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gaBgmPUqKPoXTrkBZ3FyKNXXnf1JPHJfqH1cav68DB3aGFk0M8VRAt","date":"Jun 5, 2023","link":"https://finance.yahoo.com/news/motus-gi-announces-appointment-ravit-204200618.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"management changes","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. has completed a corporate reorganization to reduce operating costs and support key value creation drivers. The company has promoted Ravit Ram as the new Chief Financial Officer (CFO) as part of the transition plan for the previous CFO, Andrew Taylor. The reorganization aligns with the companys strategic focus, including the development of the next generation of their technology, the Pure-Vu Gen 4 Gastro and Colon, which are expected to be submitted for FDA clearance in Q4 2023. The company aims to establish commercial partnerships in the future and is working on a cost structure that aligns with this goal. Ravit Ram brings extensive operational and financial experience to the role, having served as a senior member of the Motus GI management team since 2018.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["corporate reorganization","CFO appointment","FDA clearance","Pure-Vu Gen 4 Gastro and Colon","commercial partnerships"],"date_of_event":"June 5, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8uOTBhBfGwbrPnkJlA8Us7TEO0apEE438topIVZwmkJInrq3X5Sdm0","news_summary":"Motus GI Announces Appointment of Ravit Ram as Chief Financial Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dQOYaU221GlF7SxFFJJDXbDRDbo93pZGUSE7BuQ1rSglBV5oYPSRs5","date":"May 30, 2023","link":"https://finance.yahoo.com/news/now-time-look-buying-motus-125453604.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","company":"Motus Holdings Limited","layoffs":null,"summary":"The article discusses the stock price movement of Motus Holdings Limited and questions whether the current trading price is reflective of the companys actual value. It suggests that the stock is currently undervalued, providing an opportunity for investors to buy. The article also mentions that the company is expected to deliver relatively unexciting earnings growth. Shareholders are advised to consider increasing their holdings in the stock, while potential investors are encouraged to consider the future outlook of the company. The article concludes by mentioning that there are 2 warning signs for Motus Holdings. The date of the event described in the article is not provided.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["stock price movement","valuation","growth potential","undervaluation","investment decision"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LlVoMgrOq9xhzxw6h1SdWUWQHUcJi4Ea1OyxeGRbikTVwb7fHeopD0","news_summary":"Is Now The Time To Look At Buying Motus Holdings Limited (JSE:MTH)?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"vVzeXm28AwYwmGKjhIDAUk3M4fGBmJWhSmRYxqbYADTSS0Rpks8iGF","date":"May 18, 2023","link":"https://finance.yahoo.com/news/motus-gi-announces-3-5-120000679.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"private placement","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. has entered into definitive agreements for a private placement of its common stock and warrants. The private placement is expected to raise approximately $3.5 million in gross proceeds, which will be used for working capital and general corporate purposes. The offering is not a public offering and the securities have not been registered under the Securities Act. H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement. The company has also agreed to amend certain existing warrants. A registration statement will be filed with the SEC to cover the resale of the securities.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["private placement","common stock","warrants","purchase price","closing conditions"],"date_of_event":"May 19, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$3.5 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2LAEdRusfHnDvrd29mGtPu1IoqEAz6oSosaikLg3UPEXPz3d5Lzgcb","news_summary":"Motus GI Announces $3.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"taTyCxcwYIQ1Av5HjOkN8oHuuJzRfTzTdUiG9IRKpsvkNyOiUGcPGv","date":"May 17, 2023","link":"https://finance.yahoo.com/news/why-motus-gi-stock-skyrocketing-161617109.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical evaluation","company":"Motus GI Holdings Inc","layoffs":null,"summary":"Motus GI Holdings Inc shares are trading higher after the company completed the first clinical evaluation of New Pure-Vu Gastro in upper gastrointestinal (GI) procedures to support FDA submission. The evaluation showed positive results in terms of efficiency and improved bowel prep rate. Motus GI has also initiated a process to explore strategic and financing alternatives.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Pure-Vu Gastro","FDA submission","clinical evaluation","Boston Bowel Prep Scale","strategic and financing alternatives"],"date_of_event":"2023-01-25","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yxj91ocqRgtzC8iusLsNvwxqmOCC3AJ6oGgNN95BbPtVRK2Fc3y1aZ","news_summary":"Why Motus GI Stock Is Skyrocketing Today","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Z32PxiLY1sh3qAQpiZH97cYQtSjHVrZKn1II8pdanSqkFk4IGnlOQ1","date":"May 17, 2023","link":"https://finance.yahoo.com/news/motus-gi-completes-first-clinical-123000312.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"medical technology","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. has announced the initiation of a clinical evaluation of its Pure-Vu Gen 4 Gastro device in collaboration with the Ecuadorian Institute of Digestive Diseases. The device is designed for upper gastrointestinal (GI) bleeding procedures. The company plans to submit a 510(k) application to the U.S. FDA for the Pure-Vu Gastro device in Q4 2023. The clinical evaluation has shown high usability scores and positive initial feedback on the devices performance. The Pure-Vu Gen 4 Gastro device aims to improve a physicians visualization while identifying and treating upper GI bleeds. The device will also be used during the 9th IECED Live Endoscopy Course in June 2023.","partners":["Ecuadorian Institute of Digestive Diseases (IECED)"],"customers":null,"investors":null,"confidence":9,"key_topics":["Pure-Vu Gastro","clinical evaluation","upper GI bleeds","endoscopy procedures","FDA submission"],"date_of_event":"May 17, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2SqMfPxyIaXSZYmPC175Fjv6DkXbeCzxvBBUREyBOe6zJ60dwQYeKV","news_summary":"Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"UuaIAB9DvnFQ9BrbV5utksQjpSx5qCGZDxiX0dG7bXDOWELaouMa6h","date":"May 16, 2023","link":"https://finance.yahoo.com/news/motus-holdings-limited-jse-mth-091844678.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["ownership","institutional investors","stock price"],"company":"Motus Holdings Limited","layoffs":null,"summary":"The article discusses the ownership structure of Motus Holdings Limited, with institutions owning 51% of the company. The presence of institutional investors is generally viewed as a positive attribute, as they have a significant amount of resources and liquidity. The top 5 shareholders own 52% of the company. The article also mentions insider ownership, with insiders collectively owning R826m worth of the company. The general public holds a 14% stake in the company, while private companies hold 15%. The article advises considering other information and warns of 2 warning signs for Motus Holdings. The article does not provide a specific date for the event described.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["ownership","institutional investors","stock price","insider ownership","general public ownership"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PAbcdJAO2OtzZSxmBEoGW6lvaw2GdtYQkv11qMDQNPWOXrEPTSaZ8T","news_summary":"Motus Holdings Limited (JSE:MTH) is a favorite amongst institutional investors who own 51%","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d00fQtD24e6CYP3FtXaROIATe5BsCKzhNYlOYnPjcnbWAs4bfGckbq","date":"May 11, 2023","link":"https://finance.yahoo.com/news/motus-gi-announces-ddw-2023-110000558.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical outcomes, endoscopy solutions","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. announced that new clinical data from the University of Minnesota and Minneapolis VA Medical Center showed a hospital-wide improvement in the rate of incomplete bowel prep for colonoscopies after implementing the Pure-Vu EVS. The study demonstrated a decrease in canceled and poor quality procedures, leading to improved resource utilization and patient experience. The data was presented at Digestive Disease Week 2023. Motus GI believes that the implementation of Pure-Vu EVS can have a significant impact on reducing suboptimal exams or canceled procedures, improving the patient experience, and optimizing resource utilization. The company is also working with VA hospitals to be included in their 2024 budgets.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Pure-Vu EVS","clinical data","improved resource utilization","patient experience","colonoscopies"],"date_of_event":"May 6 - 9, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"68IODr9QuUQxszHzaRV6TuMQk9iv7ShAvzhI7nOcOZCG1IAfpqWFQq","news_summary":"Motus GI Announces DDW 2023 Clinical Study Presentation Showing Pure-Vu EVS Drove a 33% Hospital-Wide Improvement in Incomplete Bowel Prep Rate at Minneapolis VA Medical Center","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"HA2eafjWwYGNUfJ5qfm3tEVpxbiSosOgm5jQnwZjHwqbisMqahbhbM","date":"May 10, 2023","link":"https://finance.yahoo.com/news/motus-gi-reports-first-quarter-200500560.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"YgktHksiBPFUyEly435z8cyCIKCLKPSul6HsYn2aICVOmVz4hT1zXk","news_summary":"Motus GI Reports First Quarter 2023 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"qWSp4RIfVvjAsSMEYniCrGORmB4ATlllnw8h2w0FjSCKRNTsnS4JaA","date":"May 10, 2023","link":"https://finance.yahoo.com/news/motus-gi-holdings-inc-mots-225510533.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"gSmIdd1E4nGDQb8wuK0ha3KKhOiQ8R5iWiB7RQsAJhBscGL0ycy8hy","news_summary":"Motus GI Holdings, Inc. (MOTS) Reports Q1 Loss, Lags Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"HoGLnjQHk855wTnE9KCgKvUN7MYkCPo5f1y0MICA0Ct3lbpNR7QlLJ","date":"May 2, 2023","link":"https://finance.yahoo.com/news/those-invested-motus-holdings-jse-062546477.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"share price, earnings per share, dividends, total shareholder return","company":"Motus Holdings Limited","layoffs":null,"summary":"The share price of Motus Holdings Limited has fallen 25% in the quarter, but has seen a 219% increase over the past three years. The company has achieved compound earnings per share growth of 26% per year, lower than the average annual increase in the share price. Motus Holdings total shareholder return for the last three years was 268%, largely due to its dividend payments. Insider buying has been significant in the last quarter. While the past year has been challenging for the companys shares, the longer-term performance has been positive. However, there are some warning signs to consider. This article does not constitute financial advice.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Share price performance","Earnings per share growth","Dividends","Total shareholder return","Insider buying"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"n8mN10Tf82qxbRPpoKMgePVBMRNeXTz61CraDCwHAcUPKEWWMXY2ZS","news_summary":"Those who invested in Motus Holdings (JSE:MTH) three years ago are up 268%","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"QJy0omSbgLEDVSlapeLmW1Hbwaj1dtFXwPssCAdeV2RlyhmPobqqT8","date":"Apr 27, 2023","link":"https://finance.yahoo.com/news/angel-medical-systems-creator-guardian-123000973.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"name change","company":"Angel Medical Systems Inc. (dba AngelMed)","layoffs":null,"summary":"Angel Medical Systems Inc. has changed its corporate name to Avertix Medical Inc. and appointed new leadership roles. The companys Guardian™ product family, which provides early cardiac monitoring and alerting, has been successful and is driving growth. The name change reflects the companys commitment to continue providing the Guardian™ to patients worldwide. Tim Moran has been appointed as President and CEO, bringing his experience in the medical technology industry. Philip Tom has joined as Executive Vice President and CFO. The company aims to empower patients who have had prior acute coronary syndrome (ACS) events with state-of-the-art technology. The changes mark a pivotal time for the company as it focuses on improving long-term management of coronary disease.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Name Change","Leadership Roles","Guardian™ Product Family","Early Cardiac Monitoring","Alerting Device"],"date_of_event":"April 27, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"gWrXTjZHpdeb3Qiof2KHbzb79NxafFLecrLs5lIBk9K8HryYUTYx0X","news_summary":"Angel Medical Systems, Creator of the Guardian™, First Implantable Cardiac Alert System, Changes Name to Avertix Medical Inc. and Welcomes New CEO and CFO to Drive Continued Growth and Success","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"xZi4kHMgyQdMUka8nFmSR35Id72nbiu2A8lTyC7qFCJPDxhDEqlyWQ","date":"Apr 13, 2023","link":"https://finance.yahoo.com/news/motus-gi-announces-executive-leadership-200500938.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"executive changes, cost-cutting measures, R&D efforts, FDA submission, restructuring","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. announces executive changes and restructuring to reduce operating costs and support key value creation drivers. Tim Moran transitions from CEO to Chairman of the Board, while Mark Pomeranz is appointed as the new CEO. The company implements cost-cutting measures to reduce operating expenses by approximately 25%. The restructuring plan aims to extend the companys cash runway to support FDA submission of its Pure-Vu Upper GI and fourth-generation Lower GI products by the end of 2023. The changes are part of the companys strategy to focus on R&D efforts, bring new products to market, and support existing customers and pipeline opportunities. The company expects to incur non-recurring charges of less than $400,000 in the second quarter of 2023. Mark Pomeranz brings extensive experience in the medical device industry and has been involved in the development of the companys flagship product, the Pure-Vu System.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Executive changes","Cost-cutting measures","R&D efforts","FDA submission","Restructuring"],"date_of_event":"April 13, 2023","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Management Changes","Layoffs"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes  #Layoffs","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"8gKfzaV1i4P3vE80q50goErQOvzngUIVvE6k2Ny8h22O7ntrU9cTTG","news_summary":"Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c9sYOzg9Hztd3GVitN1RGSGmecGHL1wcyTOUf7sjZydY7mbYq6TpuF","date":"Mar 31, 2023","link":"https://finance.yahoo.com/news/motus-gi-reports-fourth-quarter-200500130.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"Y21oeMYO8UFtfTujvRx4q7MyTOqGDLyu7LZhcUHlOXmHNPy65MkOOs","news_summary":"Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Bz8kx6fa2b2p7dfcE6L6XwkZCSZ4jBAjfDPCYREcqw6uaNd4DV5a9a","date":"Mar 31, 2023","link":"https://finance.yahoo.com/news/motus-gi-holdings-inc-mots-212509042.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"xF5DzAb8S98NDwRMJcU5lGKsUlUTYC81k4KbqzSYG5Pkcgb3Wn7OIV","news_summary":"Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Lags Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Z8MFX0axJRKymdiOTXz06ufVRTzSsSYGDCTSPBzO4paLEvQehPgoww","date":"Jan 10, 2023","link":"https://finance.yahoo.com/news/motus-gi-holdings-looks-strategic-163146716.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Restructuring, Layoffs","company":"Motus GI Holdings Inc","layoffs":"Approximately 45% of workforce","summary":"Motus GI Holdings Inc is exploring strategic and financing alternatives and has engaged Lake Street Capital Markets LLC as an advisor. The board has approved a strategic restructuring program to preserve capital by reducing quarterly operating costs by approximately 35%. The company plans to eliminate about 45% of its workforce in the first quarter of 2023 to reduce cash burn. The restructuring is expected to incur a non-recurring charge of approximately $1.0 to 2.0 million in Q1 of 2023. The company reported $13.3 million in cash and cash equivalents as of September 30, 2022.","partners":"Lake Street Capital Markets LLC","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Strategic Alternatives","Workforce Reduction","Restructuring","Financial Advisory","Operating Costs"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Negative","investment_amount":"Not mentioned","structured_issues":["Layoffs","Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Layoffs  #Management Changes","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"Growth-Negative","analysisId":"b3XNvTWequF99ZWp7vg64gnBLbDvCEHCmZE0qyWlz2N1MkR7ig8u2Z","news_summary":"Motus GI Holdings Looks For Strategic Alternatives","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dbUM700DsjF71UsNZVubUPLhvRhlkUi7tNYSKvIgg7rzjFd72qGoYN","date":"Jan 10, 2023","link":"https://finance.yahoo.com/news/motus-gi-announces-exploration-strategic-133000525.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"xkKF6cP40P1t8D5XpJUcAMo40ud7IG4FgRK28FmllPFxwkosWZIrz2","news_summary":"Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring Plan","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"l75VtG3DUseRQWDe29y5GK7LxJ855dvBp0Mk7wG3sg8D8Y5QV469Fe","date":"Dec 21, 2022","link":"https://finance.yahoo.com/news/motus-gi-announces-improvement-pure-130000590.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"X73DEuskaL0ILPQGgJ9noOcpHeS4DnJOmH7sYcVowiVdJSTqlg1Clc","news_summary":"Motus GI Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"0SBPIXeZySqLXQPnfqaycEIacQI8GCOr9rvr5xWBAX0WPfB0cUZDdc","date":"Nov 17, 2022","link":"https://finance.yahoo.com/news/motus-gi-holdings-third-quarter-110505935.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"FIcnZT0HZGZj36QAG4YPYjoKVlznF4x4x7ErfAlminnX3fhlw8O71l","news_summary":"Motus GI Holdings Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"avZU4GFYl9TaHrHHwd8tfGi1WpOj6nvhAdxBP6xmvy9HgITWmO3uZ0","date":"Nov 15, 2022","link":"https://finance.yahoo.com/news/motus-gi-holdings-inc-mots-005512469.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"wPqXBUIAEgQuCM9N3vv7ce5fM67XxuNZYQz99cPS4AvCtLXF2NskA0","news_summary":"Motus GI Holdings, Inc. (MOTS) Reports Q3 Loss, Misses Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"CBiQgogRvGrBIsH4h0GBgdfplvU7Jm8N4x7f7EPGj9vM9JkzSdMGKJ","date":"Feb 14, 2022","link":"https://www.globenewswire.com/news-release/2022/02/14/2384237/0/en/Motus-GI-Receives-FDA-Clearance-to-Market-the-Pure-Vu-EVS-System.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"FDA clearance","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Pure-Vu EVS System. The new system is designed to improve the speed of set-up, enhance navigation capabilities, and overcome challenges during colonoscopies. The Pure-Vu EVS System offers significant usability advancements and is expected to accelerate adoption in the U.S. and global markets. The commercial launch is planned for the first quarter of 2022. The FDA clearance is expected to allow a greater number of physicians and hospitals to utilize the technology. Motus GI Holdings aims to improve clinical outcomes and enhance cost-efficiency in the diagnosis and management of gastrointestinal conditions.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Pure-Vu EVS System","colonoscopy","physician navigation","clinical outcomes","cost-efficiency"],"date_of_event":"2022-02-14","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KxA4sI0fJNauCGQSKKJUNT6g4ub99sJq82JVqQ4cBidkwu3zyl3gRH","news_summary":"Motus GI Receives FDA Clearance to Market the Pure-Vu® EVS System","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3e508825-84da-4052-8c42-0b4e103091bc","date":"Mar 15, 2021","link":"https://ir.motusgi.com/press-releases/detail/95/motus-gi-submits-510k-application-to-fda-for-the-pure-vu","source":"ir.motusgi.com","visible":1,"analysis":{"tags":"Management Changes, Investment, Expand","company":"Motus GI","layoffs":"Not mentioned","summary":"Motus GI has made several announcements over the past few months. These include the appointment of Ravit Ram as Chief Financial Officer, a $3.5 million private placement, the completion of the first clinical evaluation of the new Pure-Vu® Gastro system, and the restructuring of the executive leadership team. The company also reported its financial results for the first quarter of 2023 and announced plans to explore strategic alternatives to enhance shareholder value.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Appointment","Private Placement","Clinical Evaluation","Financial Results","Executive Leadership Restructuring"],"date_of_event":"Between Dec 21, 2022 and Jun 14, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$3.5 million","structured_issues":["Management Changes","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sYTzvw93lwZMyi7vPL04vVKvUFV7fTI2e3fn0mQwES63PrkjNOlkNh","news_summary":"News Releases","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4e75c0ca-c67f-4a20-806a-0963623e9ee8","date":"Jan 15, 2021","link":"https://www.motusgi.com/news-media/press-releases/detail/87/motus-gi-announces-european-clearance-of-enhanced-pure-vu","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QHJ7kQcCbQ3RD4kCy8DWua9F0tTq0BFJIfiCWltZPTHj5GMXd9n4a2","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"2f7b388c-7d52-4e38-a65e-774c5b98b361","date":"Dec 16, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/85/motus-gi-announces-clinical-compendium-of-pure-vu-system","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Vk9yBC1X3rkcZJYHG5hFZiYJgKrfHxB0PZh4Emy9QUp5s8lnFSdx9J","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"f674482e-c1d4-4586-8e8f-a0ca16e64b99","date":"Dec 2, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/84/motus-gi-and-memorial-hermann-hospital-partner-to-improve","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kbTflybklpJkuCHDpoLDvkGIc9g4sxVtlRhctMyCtj6F5preKkcEEy","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"6e1a263d-1ad0-4bda-a651-1ed3321f0c16","date":"Nov 25, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/83/motus-gi-scheduled-to-participate-in-the-piper-sandler-32nd","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vNrtRUIH4BKR8AOL59esAoMQz7BqG6xgEmUcAOxPeethN5xZSc0OvK","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"e38501b1-28bf-4121-bd26-64db43430403","date":"Nov 3, 2020","link":"https://www.globenewswire.com/news-release/2020/11/03/2119274/0/en/Motus-GI-and-NYU-Langone-Health-Partner-to-Improve-its-Inpatient-Colonoscopy-Management.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical protocol","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. is launching a new clinical protocol with NYU Langone Health to incorporate the Company’s Pure-Vu GEN2 System (Pure-Vu) with the intention to improve the management of its inpatient colonoscopies. The Pure-Vu System is a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The Company has received value analysis approval for the implementation of the Pure-Vu System at NYU Langone Health and will focus on expanding training to additional physicians and staff.","partners":"NYU Langone Health","customers":null,"investors":null,"confidence":8,"key_topics":["clinical protocol","Pure-Vu GEN2 System","endoscopy solutions","NYU Langone Health","bowel preparation"],"date_of_event":"November 03, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Sth2iTOq1ZFeq0vu5efvRVnxhsDmhbrM9N8nnoTVW1iwFPXnD1ZBhi","news_summary":"Motus GI and NYU Langone Health Partner to Improve its Inpatient Colonoscopy Management","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"149241d3-8a48-46f9-bc58-d8388e4d7465","date":"Oct 29, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/80/motus-gi-to-release-third-quarter-2020-results-and-provide","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Leadership","company":"Motus GI","layoffs":null,"summary":"The article mentions Mark Pomeranz as the Chief Executive Officer and Director of Motus GI.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Mark Pomeranz","CEO","Director"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nB5OF8Hbjq9Fb0JUaiJDehEjYuoHtnQVQO3LxQ9CacCJCdGR3u64kv","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8e9ad488-7fc9-4f70-a2a3-24650badd58c","date":"Oct 13, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/79/motus-gi-hosting-key-opinion-leader-call-on-improving","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":9,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4PwLgKGzatrih62aU6XFY6AFo6qY0ReTEwbS0kvgOkv4T8DIpO6gXw","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d5f34559-ffdd-4aa1-9a0f-95b3835df1b1","date":"Sep 14, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/78/motus-gi-expands-intellectual-property-portfolio-with","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ifCd9U1EpVq1hIVziqzsCT5eSgw3lDzi0DVuwkubvsZqNSGzdVtzSZ","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"29c3c559-5928-4269-8ec2-9f98f0073c0c","date":"Sep 10, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/77/motus-gi-scheduled-to-present-at-investor-conferences-in","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":null,"summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Mark Pomeranz","Chief Executive Officer","Director"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"knOsbcLSHEnks0dWzXVTeHgS92xxsf56ezvnM45CzO5idKecCC9PvR","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9618a45c-704b-4abd-bef2-9eea52b65372","date":"Aug 28, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/76/motus-gi-announces-pricing-of-10-million-registered-direct","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":null,"summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["CEO","Director"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"d2xOXqEYbdnjU7oIZFBkJaQJBMcUjWyk0uUr7HCpbGY4INrtUHo5mw","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"c73c3f4b-ecf1-4c0b-a661-0eebc66fda66","date":"Aug 11, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/75/motus-gi-reports-second-quarter-2020-financial-results-and","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":null,"summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["CEO","Director"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"gqyM0dRgO3cS4bNasXefjTnTuJ4qLmY09hDwNUhh6RUmiuEVNm7dAC","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9721aea3-1772-4972-a1af-fdbfeff1ab92","date":"Jul 21, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/74/motus-gi-to-release-second-quarter-2020-results-and-provide","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":null,"summary":"The article mentions Mark Pomeranz as the Chief Executive Officer and Director of Motus GI.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Mark Pomeranz","Chief Executive Officer","Director"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ucWmDck5swfGPSFGLfpohWEt85wBWwN5ga7aINJSbcngvOZtxdtotm","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3ddc2818-74c7-4007-bbaf-d2165ac9025f","date":"Jun 15, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/73/motus-gi-launches-mobile-app-to-provide-on-demand-support","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":null,"summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["CEO","Director"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"v3IIg2nVg7bnm18CE6lExm05EJDPsUtZuLp2okIAjr1KtIFFmGOYHE","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"98a200db-2c0d-43d6-99c6-f50b1dbc28fb","date":"Jun 11, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/72/motus-gi-to-present-at-the-virtual-investor-fireside-chat","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mdi2m7c3Rn1biiGgFykvQtqboYFRz5sJLoQBFvvKKUZqDIbfMK71Ow","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"3b85db5a-4478-4a96-b647-29cfb434eff6","date":"May 14, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/71/motus-gi-reports-first-quarter-2020-financial-results-and","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":null,"summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["CEO","Director"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UvnRgcck4YnHck3g1DsJaxFv0L1BgrbAl2Vi2ttWqA6afYE0g9dGgV","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dbe6625c-c800-4e55-900a-813ac035e573","date":"May 5, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/70/motus-gi-expands-intellectual-property-portfolio-with-u-s","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Management Changes","company":"Motus GI","layoffs":null,"summary":"The article mentions Mark Pomeranz as the Chief Executive Officer and Director of Motus GI.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Mark Pomeranz","CEO","Director"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3mHkc8adxozFccuq9j6gvvZd95okOeWTlOSQ0FAcgyf0oWyxOWa7y5","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"28f0abc9-90ba-48dd-ab02-d3e70f73e97e","date":"May 4, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/69/motus-gi-to-release-first-quarter-2020-results-and-provide","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"O2xcxeJCRx4pchiX9dEwKw995oRArzJEubKTpHA7nnLunf75D20pfu","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"1fb3205d-e0ee-4ca1-876c-c7c6e876eb74","date":"Apr 7, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/68/motus-gi-receives-approval-from-the-israeli-ministry-of","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nmTjCWt9GlSG0giwMM1bImjP2YygD7OQhZEMXr7WrDd7CZV4BAqCwr","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ec3a2d47-cc2a-4824-a881-f066064595ed","date":"Mar 30, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/67/motus-gi-reports-fourth-quarter-and-year-end-2019-financial","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EEgotqOErrDIDWe7wqqo8gJ6LzSZ47gqDwHt4F3nUpLfe5DO3PFE8H","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9b7f89e9-759a-47ca-bf35-83f52da6a1c3","date":"Mar 27, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/66/motus-gi-receives-ce-mark-approval-for-gen2-pure-vu-system","source":"www.motusgi.com","visible":1,"analysis":{"tags":"leadership","company":"Motus GI","layoffs":null,"summary":"The article mentions Mark Pomeranz as the Chief Executive Officer and Director of Motus GI.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Mark Pomeranz","CEO","Director"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2zWhV4T8CWmVdyQEpTU1TPi9Rufsh0MwPlJYTl44geCmqshHPS1rx9","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8c5b9d08-df46-486f-9c36-68b8948114bb","date":"Mar 12, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/65/motus-gi-moving-corporate-headquarters-to-greater-boston","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Executive","company":"Motus GI","layoffs":"","summary":"The article provides contact information for Mark Pomeranz, the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["CEO","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":[],"acquisition_amount":"","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"axegk1KMDciyiiRKrmZOtZiokDHrYi17Qrqdoe5VtYV3fgnlSC1A4C","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"f2449f55-424c-4c68-a95a-ed21e42d8f91","date":"Mar 4, 2020","link":"https://www.motusgi.com/news-media/press-releases/detail/64/motus-gi-to-release-fourth-quarter-2019-results-and-provide","source":"www.motusgi.com","visible":1,"analysis":{"tags":"Management Changes","company":"Motus GI","layoffs":"","summary":"The article mentions Mark Pomeranz as the Chief Executive Officer and Director of Motus GI.","partners":"","customers":"","investors":"","confidence":8,"key_topics":["Mark Pomeranz","Chief Executive Officer","Director"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":["Management Changes"],"acquisition_amount":"","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4aPqB7Go2pxn1dvO4dumUKXOlDN8iBQnMUSbLKIMIYzwcUl5Pb5pPP","news_summary":"News Releases  Motus GI Holdings, Inc.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c0dfa140-8325-48cd-83f9-c6731711a93e","date":"Feb 13, 2020","link":"https://www.businesswire.com/news/home/20200213005224/en/Motus-GI-Participate-Life-Science-Intelligence-Emerging","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"RY0Zz1sMub3Ppo0bxXiMC1SPCN4U1QRmXTNYEJx7AZgHoLKYFmNbDE","news_summary":"Motus GI to Participate in Life Science Intelligence Emerging Medtech Summit 2020","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ead938c0-8e59-4030-bb8b-dcdef29bff2d","date":"Nov 11, 2019","link":"https://www.businesswire.com/news/home/20191111005062/en/Motus-GI-Announces-EXPEDITE-Study-Initiated-Boston","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"pW6gA5UdKVqQ47uWoBrdRJUtP8aSsuzDAzyEtV49rhffC9vaySoBww","news_summary":"Motus GI Announces EXPEDITE Study Initiated by Boston Medical Center to Evaluate Clinical Effectiveness of Pure-Vu® System for Improving Bowel Preparation Rates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"abd44528-403b-49c8-856e-d455d4e2bcf3","date":"Jul 11, 2019","link":"https://www.massdevice.com/motus-gi-lands-fda-clearance-for-next-gen-colon-prep-system/","source":"www.massdevice.com","visible":1,"analysis":{"tags":"medical devices","company":"Motus GI","layoffs":null,"summary":"Motus GI has received FDA 510(k) clearance for the second-generation of its Pure-Vu colonoscopy device. The new device is designed to improve mobility, setup logistics, and navigation through the colon while retaining the same cleansing functionality as the first generation. The company plans to launch the Pure-Vu system this year and aims to establish it as a new standard of care in key endoscopy segments. The initial focus will be on the inpatient colonoscopy market, where challenges with insufficient bowel prep can lead to canceled procedures, delayed diagnosis, and increased costs for hospitals.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["FDA clearance","Pure-Vu colonoscopy device","Improved mobility and setup logistics","Inadequate bowel preparation","Planned commercial launch"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9fiPpiE8SnsIOqkaGMqAjduzkqEv78jFZAhxiTnE1xmRqjPH5fO7rE","news_summary":"Motus GI lands FDA clearance for next-gen colon prep system","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"97769b87-c491-421c-ab79-ee55fb5dc2c0","date":"May 20, 2019","link":"https://www.businesswire.com/news/home/20190520005186/en/Motus-GI-Presents-Positive-Clinical-Results-REDUCE","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"Y9OlHJ9KDbe0OjCRdpOHAkv1hmapMgeMPqO0Xyup9w9hmWqTqX1rFz","news_summary":"Motus GI Presents Positive Clinical Results from REDUCE Study Evaluating Pure-Vu® System in Hospitalized Colonoscopy Patients at Digestive Disease Week® 2019","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d4f6fb8e-8df7-4d79-9c6d-ad6bcc21acdc","date":"Feb 19, 2019","link":"https://www.businesswire.com/news/home/20190219005192/en/Motus-GI-Announces-Publication-Pure-Vu%C2%AE-System-Clinical","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"U60PWDBDxEtrnKrRszHdX13O0uTV0n1e36fCPwhxQEY7zosSFTaUpS","news_summary":"Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Journal of Clinical Gastroenterology","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"4d0cc334-7c49-4fb2-8ea9-2e18b4f1be6c","date":"Jan 3, 2019","link":"https://www.biospace.com/article/releases/motus-gi-announces-publication-of-pure-vu-system-clinical-study-data-in-peer-reviewed-endoscopy-journal/","source":"www.biospace.com","visible":1,"analysis":{"tags":"medical device","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc., a medical technology company, has announced the publication of data from a feasibility study of its flagship product, the Pure-Vu System. The study showed that the Pure-Vu System significantly increased the number of subjects with an adequate cleansing level during colonoscopy procedures. The data supports the companys belief that the Pure-Vu System can become the standard of care in the inpatient market and support high-need segments in the outpatient market. Motus GI is currently focused on post-approval clinical trials and market development programs with leading US hospitals in preparation for a full commercial launch in the US and select international markets in 2019.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Pure-Vu System","clinical trials","market development","colonoscopy","feasibility study"],"date_of_event":"2019-01-03","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BmEf81CVMrhnPD2xv3unTz2TbZRtx0RH9xCC1xVcE7dDAkYMZSkQ3q","news_summary":"Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Endoscopy Journal  BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7887f2da-c1ea-4929-80a6-311f76c60080","date":"Dec 19, 2018","link":"https://www.businesswire.com/news/home/20181219005906/en/%C2%A0Motus-GI-Announces-13.5-Million-Follow-on-Public","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ZKHqvQBK00sdJHCwgeSX20AZ0shFVuH4V0I7auNqRBozuvnvLX7avB","news_summary":"Motus GI Announces $13.5 Million Follow-on Public Offering","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ea3f9f27-28ff-459d-bc68-c1b4bd149a6f","date":"Nov 20, 2018","link":"https://www.businesswire.com/news/home/20181120005049/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"xCUBAKNBD3isAV19gk7gHxxRnxMFhDbWn1oDVtqkiLfiPOfffl3lot","news_summary":"Motus GI to Present at the Piper Jaffray Healthcare Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"777f7ef3-6ae1-4d19-85c9-bbcbf938f912","date":"Nov 8, 2018","link":"https://www.businesswire.com/news/home/20181108005207/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"WzIONkRyGDs2I1aSHxRlyqz45erQZBxaVVP8o475eGPciXlcdZ2jmL","news_summary":"Motus GI Announces Successful Clinical Use of Pure-Vu® Slim Sleeve with Slim Colonoscopes","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"cbd9d373-e528-4c6b-a332-c33c415504cc","date":"Oct 10, 2018","link":"https://www.businesswire.com/news/home/20181010005257/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"hUTAf7ihOxfDCmo6MBFkIupI0DzGah1zsIDpvIHHTLthwCYHJ2ZGrn","news_summary":"Motus GI Presents Positive Clinical Data from U.S. Prospective Study of the Pure-Vu® System at the 2018 American College of Gastroenterology (ACG) Annual Meeting","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"5080c7f0-628b-41fa-b413-9685c18068f5","date":"Sep 25, 2018","link":"https://www.businesswire.com/news/home/20180925005206/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"k8YWBXp1FFkiK2w9Y91irCVkJuOGCfYVc1f2jjb0WhRO24vgmMnDoQ","news_summary":"Motus GI Appoints Medical Device Commercial Leader Timothy P. Moran as Chief Executive Officer;Mark Pomeranz Continues in Key Executive Leadership Role as President and Chief Operating Officer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9a90abe5-b070-420d-a0fd-c79465c11491","date":"Sep 13, 2018","link":"https://www.businesswire.com/news/home/20180913005214/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"w6jhaYi83iiRdFqTsZFhFE9IUt6SrQdDGIGLELsuFLHuglD56Z16Ac","news_summary":"Motus GI Receives FDA Clearance to Market Pure-Vu® Slim Sleeve for Use with Slim Colonoscopes","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"35491722-68cf-4094-9b37-a63b7beb872c","date":"Aug 9, 2018","link":"https://www.businesswire.com/news/home/20180809005139/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Management Changes, Expand","company":"Motus GI Holdings, Inc.","layoffs":"N/A","summary":"Motus GI Holdings, Inc., a medical technology company focused on improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, has announced the appointment of Jeff Hutchison as Vice President of U.S. Sales and Commercial Operations. Hutchison will be responsible for building Motus GI’s U.S. sales organization and driving the company’s pre-launch commercial activities ahead of the planned launch of the Pure-Vu® System into the inpatient market in 2019. The Pure-Vu® System is a FDA-cleared medical device system that enables physicians to rapidly cleanse the colon during the colonoscopy procedure.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":10,"key_topics":["Appointment","Sales","Commercial Operations","Medical Device","Colonoscopy"],"date_of_event":"20180809","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0pvEiG5OFENhUGiLgMg2len7bbOCpnTI9AGRuOmFckkxSZ5bcZvKXY","news_summary":"Motus GI Appoints Jeff Hutchison as VP of U.S. Sales and Commercial Operations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"77b9b6ec-92d9-4e72-ad12-1e64ecb322c4","date":"Jul 30, 2018","link":"https://www.businesswire.com/news/home/20180730005055/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"xdyQ71qoUYQabAtQ22TKKl8WlrRUMPtQhoAJuQN19nxDMCeyG7j55J","news_summary":"Motus GI Strengthens IP Portfolio with Issuance of Japanese Patent for the Pure-Vu® System","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"57d7cb6d-2ad7-472d-baaa-661935f18b1a","date":"Jun 25, 2018","link":"https://www.businesswire.com/news/home/20180625005103/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ykY6xSVW7dqPRENlci3gwZ5k63ipOsQ6rk3mKID0dzvJOsc9nfDKpC","news_summary":"Motus GI Announces Inclusion in the Russell Microcap® Index","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9758f841-7530-4572-9e42-8c9f5415cc6c","date":"Jun 4, 2018","link":"https://www.beckersasc.com/gastroenterology-and-endoscopy/motus-gi-s-pure-vu-system-can-lower-repeated-colonoscopy-procedure-cost-by-up-to-82.html","source":"www.beckersasc.com","visible":1,"analysis":{"tags":"medical technology","company":"Motus GI","layoffs":null,"summary":"Motus GIs Pure-Vu System has been shown to lower repeat colonoscopy cost and colorectal cancer incidence rate by improving colon prep. The system reduced the colorectal cancer incidence rate by 36% and minimized overall patient costs by up to $3,400 for private payers and up to $1,600 for Medicare beneficiaries. It also reduced the costs of repeated procedures due to inadequate prep. The research findings were presented at Digestive Disease Week.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Pure-Vu System","colonoscopy","cost reduction","colorectal cancer","research findings"],"date_of_event":"June 2 to June 5","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bI0VGcrdVHdSrORwsVjetPS576hcwasbg3os4bu8Z2OTpI2TRmP3AU","news_summary":"Motus GI's Pure-Vu System can lower repeated colonoscopy procedure cost by up to 82%","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"38e5f6eb-aa6e-4562-a7a0-422c78b24087","date":"May 21, 2018","link":"https://www.businesswire.com/news/home/20180523005413/en/Motus-GI-Enrolls-Patient-REDUCE-Study-Pure-Vu%C2%AE","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Medical Technology, Endoscopy","company":"Motus GI Holdings, Inc","layoffs":"N/A","summary":"Motus GI Holdings, Inc has enrolled the first patient in its REDUCE study, a multi-center, prospective study that will use the Pure-Vu System to facilitate bowel cleansing in approximately 100 hospitalized patients who are indicated for a diagnostic colonoscopy procedure. The Pure-Vu System is a medical device that cleans the colon intra-procedurally to facilitate improved visualization during a colonoscopy procedure. The REDUCE study is designed to evaluate the Pure-Vu Systems ability to consistently and reliably cleanse the colon to facilitate a successful colonoscopy in a timely manner.","partners":"N/A","customers":"Hospitalized Patients","investors":"N/A","confidence":9,"key_topics":"REDUCE Study, Pure-Vu System, Colonoscopy, Bowel Cleansing, Hospital Efficiency","date_of_event":"23 May 2018","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0U7meVQ32pTlLKJQv0EQ1Dg8GddB6lJXkVqbWx0AonM4gCxe7gsBWz","news_summary":"Motus GI Enrolls First Patient in REDUCE Study of the Pure-Vu® System in Hospitalized Patients","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6c70a536-76c4-4ca1-828a-54b7154a2515","date":"May 21, 2018","link":"https://www.businesswire.com/news/home/20180521005309/en/Motus-GI-Announces-Issuance-Chinese-Patent-Pure-Vu%C2%AE","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"cieIpCkpkDto5IgYYYawNhOUEsIODnkbUnQlI89RYFQk7lDJ7rtaOg","news_summary":"Motus GI Announces Issuance of Chinese Patent for the Pure-Vu® System","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"c6dc9587-1844-4440-93fa-d869026c36d5","date":"Mar 27, 2018","link":"https://www.businesswire.com/news/home/20180327005222/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Patent, Medical Technology","company":"Motus GI Holdings, Inc.","layoffs":"N/A","summary":"Motus GI Holdings, a medical technology company, has been granted a patent by the US Patent and Trademark Office for its Pure-Vu System, a device that cleans the colon to facilitate improved visualization during a colonoscopy procedure. The company is planning to launch the product in the US and select international markets in 2019. The Pure-Vu System is currently being introduced on a pilot basis in the US market. The company believes the system can improve colonoscopy procedures, improving speed of diagnosis and clinical outcomes while potentially saving hospitals thousands of dollars per patient.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Patent Issuance","Medical Device","Endoscopy","Colonoscopy","Market Launch"],"date_of_event":"2018-03-27","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Investment","acquisition_amount":"N/A","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2BYJZMgELh8KGH1BN02J45ZaoFr2031CnAHfFvv6jyTw1wouw34UPR","news_summary":"Motus GI Expands Intellectual Property Portfolio with New U.S. Patent Issuance for the Pure-Vu® System","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7df99447-039c-48ef-bd18-b10cedfbf252","date":"Mar 20, 2018","link":"https://www.businesswire.com/news/home/20180320005280/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"KBwWd87NoVZSUzX4PVOLGjN8BOr3c5yKjZFnv1KMzmP1JuD1gCMnS9","news_summary":"Motus GI Announces Issuance of European Patent for the Pure-Vu® System","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"e288e8ef-df30-48a6-989f-cc53d30e87ae","date":"Feb 27, 2018","link":"https://www.businesswire.com/news/home/20180227005507/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"BZqAe82UjfoeAAsw5Zyj2lTXNZyvA6n2yAwXrM5SfXiQUkWscilqF9","news_summary":"Motus GI Receives CE Mark Approval for the Pure-Vu® System","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"bdac248b-d0f8-4869-bb77-c870f0f3b278","date":"Feb 16, 2018","link":"http://markets.businessinsider.com/news/stocks/Motus-GI-Announces-Closing-of-Initial-Public-Offering-1016058813","source":"markets.businessinsider.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"cUMpGEBMhym08Tyg453gXOYY8o058n47XnchQ98rWVsDm3LSdwSM3L","news_summary":"Motus GI Announces Closing of Initial Public Offering","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d22a5e39-4daf-4c5f-9446-e3243f1b2de6","date":"Feb 28, 2017","link":"http://finance.yahoo.com/news/motus-gi-holdings-inc-successfully-123000244.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"medical device","company":"Motus GI Holdings, Inc.","layoffs":null,"summary":"Motus GI Holdings, Inc. has announced the closing of a $30.0 million private placement to support the U.S. commercial launch of its Motus Pure-Vu system for cleaning poorly-prepped colons during colonoscopies. The lead investor in the private placement was Perceptive Advisors, with additional investments from Orchestra Medical Ventures, Ascent Biomedical Ventures, Jacobs Investment Company, GJG Life Sciences, and Pura Vida Investments. The net proceeds from the private placement will be used to build awareness and support for the Pure-Vu systems benefits among providers, patients, and payers. The Pure-Vu system has the potential to significantly improve colonoscopy outcomes and reduce costs associated with inadequate bowel prep. Motus GI Holdings received clearance from the U.S. Food and Drug Administration to market the Pure-Vu system in September 2016.","partners":null,"customers":null,"investors":["Perceptive Advisors","Orchestra Medical Ventures","Ascent Biomedical Ventures","Jacobs Investment Company","GJG Life Sciences","Pura Vida Investments"],"confidence":8,"key_topics":["private placement","Motus Pure-Vu system","colonoscopy outcomes","U.S. commercial launch","bowel prep"],"date_of_event":"2017-02-28","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$30.0 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HmZShsBQBvldflk13nrZmv653Sv4XPQwOiIfNN6mGFuudvB0zoZHUx","news_summary":"Motus GI Holdings, Inc. Successfully Completes $30.0 Million Private Placement","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"58222554-6e3f-4915-870e-e2ce933d408e","date":"Nov 1, 2016","link":"http://www.massdevice.com/motus-gi-touts-pure-vu-clinical-data/","source":"www.massdevice.com","visible":1,"analysis":{"tags":"colonoscopy, healthcare","company":"Motus GI","layoffs":null,"summary":"Motus GI, a healthcare company, has developed the Pure-Vu cleansing device to improve the preparation of patients for colonoscopies. According to Motus GI CEO Mark Pomeranz, 20% of colonoscopy patients are poorly prepped, leading to the need for a second visit and potential missed cancerous lesions. Motus GIs Pure-Vu system, which is integrated with a standard colonoscope, significantly increased the number of participants with adequately cleansed colons in a clinical trial. Inadequately prepped colons not only burden the healthcare system but also impact physician reimbursement. Motus GI received FDA clearance for the Pure-Vu system in 2016 and plans to pursue CE Mark approval in the European Union.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["colonoscopy","Pure-Vu cleansing","clinical trial","reimbursement","FDA clearance"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bG1NnNr07fqu9AsKgUelvAueib6SFFA6Yrteb6tV2o2EBsOREAogWo","news_summary":"Motus GI touts Pure-Vu clinical data","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8403aa81-d001-4568-a522-e7700ea7a876","date":"Oct 10, 2016","link":"https://www.medgadget.com/2016/10/pure-vu-colonoscopy-system-cleansing-dirty-colons.html","source":"www.medgadget.com","visible":1,"analysis":{"tags":"medical device","company":"MOTUS GI","layoffs":null,"summary":"MOTUS GI, an Israeli firm, has developed the Pure-Vu system, an FDA-cleared system that helps with bowel cleansing during colonoscopies. The system uses sprinklers and a suction channel to clear the colon, making it easier to detect polyps. The system does not obstruct the colonoscope or its working channels, allowing for other procedures to be performed. The article includes an animation demonstrating how the system works.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["colonoscopy","FDA-cleared system","Pure-Vu system","bowel cleansing","MOTUS GI"],"date_of_event":"October 10th, 2016","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6DeVwLk6ukFU4AYfzceFp5qUHO42ubRUZsW1EAVkXM55vDZarRfa0p","news_summary":"Pure-Vu Colonoscopy System for Cleansing Dirty Colons","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"57132e51-c773-4f44-80a8-6b4bd353ae01","date":"Oct 4, 2016","link":"https://medcitynews.com/2016/10/colorectal-cancer-fda-clearance/","source":"medcitynews.com","visible":1,"analysis":{"tags":["medical technology","colonoscopy","screening compliance"],"company":"MOTUS GI","layoffs":null,"summary":"MOTUS GI has received FDA clearance to market its Pure-Vu system, a device that helps cleanse poorly prepped colons during colonoscopy procedures. The system consists of a disposable component and a workstation controller and uses a mixture of water and air to loosen debris from the colon mucosa. The device aims to address the issue of inadequate colon preparation, which often leads to repeat procedures, missed adenomas, reduced patient satisfaction, and higher costs. MOTUS GI plans to target both the hospital in-patient market and the outpatient market, with the potential to revolutionize the colonoscopy experience and improve patient care and satisfaction.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["colonoscopy","screening compliance","Pure-Vu system","market opportunity","patient satisfaction"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7ejEtFT2Seb1ocAiwZKVdxFcAOpZYIaIutN3zycQxPD7cHEePtljew","news_summary":"Device offering colonoscopy workaround to boost compliance wins FDA clearance","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"90167c99-89d9-487c-b1ea-f6b9f729ac75","date":"Sep 26, 2016","link":"https://www.beckersasc.com/gastroenterology-and-endoscopy/fda-clears-pure-vu-system-for-intra-procedural-colon-cleaning-3-notes.html","source":"www.beckersasc.com","visible":1,"analysis":{"tags":"medical device","company":"MOTUS GI","layoffs":null,"summary":"Israeli medical device company MOTUS GI has received FDA clearance for its Pure-Vu System. The system cleans poorly-prepared colons during a colonoscopy procedure, allowing for colorectal cancer screening regardless of a patients prior activities. It includes a disposable cleaning component that fits over a standard colonoscope, helping physicians obtain a clear visualization of the colon wall. MOTUS GI expects the device to decrease prolonged procedure times, missed adenomas, and repeat exams caused by inadequate patient preparation.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Pure-Vu System","colonoscopy procedure","colorectal cancer screening","disposable cleaning component","decrease procedure times"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VaBQ3bJhbdWT0IPwO4A4jM9UadSBX11c9VKxz8oOmELW6gqqWVB8L8","news_summary":"FDA clears Pure-Vu System for intra-procedural colon cleaning: 3 notes","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":104,"techcommunityinvolvement":null,"mediagallery":[{"id":"4a93e3fb-1f6c-41c7-8d21-38450fd04943","timestamp":"2020-12-06 08:36:05.000000","resources_type":1,"resources_title":"","resources_file_name":"$781w268mSigSVIqatU0FGjyEdMxst7LOQSALmBtyvSa6l7oAWI6fjM","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$781w268mSigSVIqatU0FGjyEdMxst7LOQSALmBtyvSa6l7oAWI6fjM","url":"https://storage.googleapis.com/clean-finder-353810/$781w268mSigSVIqatU0FGjyEdMxst7LOQSALmBtyvSa6l7oAWI6fjM"},{"id":"730cc4d8-40c0-477e-b841-de0c50c8b927","timestamp":"2020-12-06 08:35:03.000000","resources_type":1,"resources_title":"Workstation with cart, no tubing","resources_file_name":"$1PzsTuHYvlo6ubQcfSk6z7cghkWpEmtSRr2gBJsZlOI86V8KV5orGD","alt":"Workstation with cart, no tubing logo","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$1PzsTuHYvlo6ubQcfSk6z7cghkWpEmtSRr2gBJsZlOI86V8KV5orGD","url":"https://storage.googleapis.com/clean-finder-353810/$1PzsTuHYvlo6ubQcfSk6z7cghkWpEmtSRr2gBJsZlOI86V8KV5orGD"},{"id":"40a6522f-dbc4-4f55-b061-1b81da4220fc","timestamp":"2017-11-23 21:16:28.000000","resources_type":2,"resources_title":"","resources_file_name":"r3Vn0Twng9w","alt":"","imageurl":"https://img.youtube.com/vi/r3Vn0Twng9w/0.jpg","url":"http://youtu.be/r3Vn0Twng9w"},{"id":"470c31e9-74ac-4e3d-a3ff-6d3c7f6a3ff3","timestamp":"2017-11-23 21:09:59.000000","resources_type":2,"resources_title":"","resources_file_name":"OKqfooKXQoQ","alt":"","imageurl":"https://img.youtube.com/vi/OKqfooKXQoQ/0.jpg","url":"http://youtu.be/OKqfooKXQoQ"}],"tags":["medical-devices","colonoscopy","gastroenterology","cancer","healthcare-providers","diagnostics","early-detection","doctors","hospitals","sensors","medical-technologies","endoscopy"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":["Pure-Vu"],"geomarkets":["United States","Europe","China","Japan"],"targetmarkets":[],"marketcapital":639,"marketcapitaldate":"2025-09-01T13:05:28.000Z","funding":{"investors":9,"lastfunding":"$3.5M","totalrounds":5,"fundingstage":"Public","totalfunding":"$64.5M","publicinvestors":9,"lastpublicfunding":3500000,"totalpublicrounds":5,"totalpublicfunding":64500000},"team":[{"name":"Mark  Pomeranz","email":"mark@motusgi.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoJmWmKIKDA","bounced":false,"claimed":1,"founder":0,"urlname":"mark-pomeranz","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICA8bKq4ggM","position":"President & COO","last_name":"Pomeranz","claimtoken":"ce9441bab67be60329bbcc9b947ac2ceca572784e2a33f60ffed092158565553","first_name":"Mark ","picturekey":null,"claimeddate":"2020-11-17","linkedinurl":"https://www.linkedin.com/in/melissa-kim-mallach-4667bab0/","unsubscribed":false,"is_activeuser":1,"additionalemail":"melissa@motusgi.com","claimedemaildate":"2020-11-17 07:55:02.000000","initials":"MP","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Timothy P. Moran","email":"tim@motusgi.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4MT9q5AJDA","bounced":false,"claimed":0,"founder":0,"urlname":"timothy-p-moran","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDglM792goM","position":"CEO ","last_name":"P. Moran","claimtoken":"Fm9gI2y5aO1TDfhLde9chFuzJV9z2gQJNGwY9FpFDPtmRqxPv7ODaW","first_name":"Timothy","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/timothypmoran/","unsubscribed":false,"is_activeuser":1,"additionalemail":"timothy@motusgi.com","claimedemaildate":"2023-10-25 13:16:53.000000","initials":"TP","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ravit  Ram","email":"ravit@motusgi.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoKOyiPMIDA","bounced":false,"claimed":0,"founder":0,"urlname":"ravit-ram-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg44Ct7AoM","position":"VP Operations & IL Site Manager","last_name":"Ram","claimtoken":"8PUVGdp0b3mZPvgvYSu41SLZj1tBJu2R8KrJ3Emg0nnXrEVjsFNRNj","first_name":"Ravit ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ravit-ram-a3102b8/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-10-25 13:16:57.000000","initials":"RR","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Jeff  Hutchison","email":"jhutchison@motusgi.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4IOs24sJDA","bounced":false,"claimed":0,"founder":0,"urlname":"jeff-hutchison","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg4-vTkQkM","position":"Vice President of Sales and Commercial Operations ","last_name":"Hutchison","claimtoken":"U5u3dswkYHdPlaSFtV0cziJ8aq57W4yisoWAVxoePGIaH2yn0Bv9ip","first_name":"Jeff ","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-09-28 13:08:35.000000","initials":"JH","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Scott  Aldrich Jr. ","email":"saldrich@motusgi.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4P2f_pgJDA","bounced":false,"claimed":0,"founder":0,"urlname":"scott-aldrich-jr","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgw7PtiQkM","position":"Vice President, Global Marketing & Strategy","last_name":"Aldrich Jr. ","claimtoken":"zX4uKLujSky9HqXaXqcI3kRCPLvESZDJZOS2LBEmJLbyNiCl1DzyzO","first_name":"Scott ","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-09-28 13:08:47.000000","initials":"SA","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-03-03T00:00:00.000Z","crunchbaseid":"mouts-gi","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":null,"creator_email":null,"createdate":"2014-12-28T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"LNiZtnALp6fuRGMDVXzUls96FBAZMRXwrLhXT21Ytlm72wPzzSauEe","date":"May 2023","amount":"$3.5M","source":"https://finance.yahoo.com/news/motus-gi-announces-3-5-120000679.html","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"Xb4uJ8dEtwbfxk2NAnmcjIgGJRytcrt6Dys0PQIWuid9xDuLbWwOMY","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":3500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"FHLi9j4fZdadLRLxlyX5YDoRXaVlGrTP9gsWhEfzfbFGe9h9mRbJ0L","date":"Jul 2021","amount":"$12M","source":"https://www.biospace.com/article/releases/motus-gi-secures-expanded-12m-credit-financing-to-support-growth-strategy/","eventtype":"FundingRoundEvent","investment":[{"name":"Kreos Capital","type":"Investor","amount":null,"hidden":false,"country":"United Kingdom","fullurl":"/investor_page/kreos-capital","logokey":"$rMGVDhVjpS6PRtxsVudsf1xQNl7qCOcmiUBbjGSAtv7OOfYUIiAr2j","tagline":null,"urlname":"/investor_page/kreos-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKH-64UKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0LnG2CCObUVmSXI2lT92Ch9a8fiTBxFqowuIbkCVG0DPDXf7uc05NA","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$rMGVDhVjpS6PRtxsVudsf1xQNl7qCOcmiUBbjGSAtv7OOfYUIiAr2j","leadcaption":"Lead&nbsp;","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":12000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCIiO-fCAw","date":"Feb 2018","amount":"Undisclosed","source":"","ticker":"MOTS","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$17.5M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":17500000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEyOf6CQw","date":"Feb 2017","amount":"$30M","source":"https://www.massdevice.com/motus-gi-raises-30m-pure-vu-colonoscopy-system/","eventtype":"FundingRoundEvent","investment":[{"name":"Ascent Biomedical Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/ascent-biomedical-ventures","logokey":"$R82UOZRDEyNj11omTifywZ0ewY2onFCh3A75M3GrCJ6fN0mYS8NKz0","tagline":"","urlname":"/investor_page/ascent-biomedical-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkmqncCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"311ec2e8-89b5-42a2-a236-7f2d6d32bd40","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$R82UOZRDEyNj11omTifywZ0ewY2onFCh3A75M3GrCJ6fN0mYS8NKz0","leadcaption":"","followupcaption":""},{"name":"Perceptive Advisors","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/perceptive-advisors","logokey":"$JIoRfOrNs82qw90NI079706rsn7DcxX85uRs7vdsV7xdzkz6WDfUGC","tagline":"","urlname":"/investor_page/perceptive-advisors","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODkwMnkCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8f9beeb3-806e-4ce3-8610-f1822d24b0fc","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JIoRfOrNs82qw90NI079706rsn7DcxX85uRs7vdsV7xdzkz6WDfUGC","leadcaption":"","followupcaption":""},{"name":"Pura Vida Investments","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/pura-vida-investments","logokey":"$zr7GbV4SuI3rKRMAqfnrYwgAwwReI7qR0fZcPuBDRgY1o8Tx1sFfkL","tagline":"","urlname":"/investor_page/pura-vida-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk2uqXCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"956ad2fb-b40b-4060-aed8-ac79c6aba179","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$zr7GbV4SuI3rKRMAqfnrYwgAwwReI7qR0fZcPuBDRgY1o8Tx1sFfkL","leadcaption":"","followupcaption":""},{"name":"Jacobs Investment Company","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/jacobs-investment-company","logokey":null,"tagline":"","urlname":"/investor_page/jacobs-investment-company","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODE1c7HCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"98db2c5b-eca9-45d2-849a-106739ff94c8","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Orchestra Medical Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/orchestra-medical-ventures","logokey":"$rdrHQ11Abn8hYgUXt8rIKFuASZQZkKV1dURdrFMX47ev1eSeWupQIS","tagline":"","urlname":"/investor_page/orchestra-medical-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk2uqXCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"cb060120-50d8-4181-a485-2e14db4994d5","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$rdrHQ11Abn8hYgUXt8rIKFuASZQZkKV1dURdrFMX47ev1eSeWupQIS","leadcaption":"","followupcaption":""},{"name":"SternAegis Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/sternaegis-ventures","logokey":"$c72MUZoNAnhahMreGq8lbUCOwVHXbIiwl596VDkXESOh5bsC5WiTLs","tagline":"","urlname":"/investor_page/sternaegis-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCko46TCww","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"f73f5731-c8e3-41e8-9b07-ce852c425172","fundingsubtype":"Corporate VC","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$c72MUZoNAnhahMreGq8lbUCOwVHXbIiwl596VDkXESOh5bsC5WiTLs","leadcaption":"","followupcaption":""},{"name":"GJG Life Sciences","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/gjg-life-sciences","logokey":null,"tagline":"","urlname":"/investor_page/gjg-life-sciences","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODkwMnECgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"fb39c524-8120-449b-b3dc-02339b6c308b","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":30000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCE7s-xCgw","date":"Sep 2011","amount":"$13.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"96111c34-63bd-440b-82cc-fdd0053309ec","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":13500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"10/2008","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Motus GI","logourl":"https://storage.googleapis.com/clean-finder-353810/$DrLICg22Ro9VZETHk3GFHLEbfL2EWXgZaBpkxaIizZtW8IIxoHTRTY","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$DrLICg22Ro9VZETHk3GFHLEbfL2EWXgZaBpkxaIizZtW8IIxoHTRTY","seoabout":"Motus GI is a medical technology company dedicated to improving endoscopy outcomes and experiences. The company is currently focused on bringing to market ...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Diagnostics Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Sensing","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","TechnologyClassificationModel>Sensing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Diagnostics Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Diagnostics Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Sensing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Medical Devices","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Diagnostics Devices","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Diagnostics Devices"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Sensing","key":"0-0","path":"TechnologyClassificationModel>Sensing"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Diagnostics Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Sensing","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LvQ9JYJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Medical Devices","Diagnostics Devices"],"coreTechnology":["Sensing"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCIiO-fCAw","date":"Feb 2018","amount":"Undisclosed","source":"","ticker":"MOTS","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$17.5M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":17500000,"valuationnumber":null}],"privateequityfunding":[{"id":"LNiZtnALp6fuRGMDVXzUls96FBAZMRXwrLhXT21Ytlm72wPzzSauEe","date":"May 2023","amount":"$3.5M","source":"https://finance.yahoo.com/news/motus-gi-announces-3-5-120000679.html","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"Xb4uJ8dEtwbfxk2NAnmcjIgGJRytcrt6Dys0PQIWuid9xDuLbWwOMY","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":3500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"FHLi9j4fZdadLRLxlyX5YDoRXaVlGrTP9gsWhEfzfbFGe9h9mRbJ0L","date":"Jul 2021","amount":"$12M","source":"https://www.biospace.com/article/releases/motus-gi-secures-expanded-12m-credit-financing-to-support-growth-strategy/","eventtype":"FundingRoundEvent","investment":[{"name":"Kreos Capital","type":"Investor","amount":null,"hidden":false,"country":"United Kingdom","fullurl":"/investor_page/kreos-capital","logokey":"$rMGVDhVjpS6PRtxsVudsf1xQNl7qCOcmiUBbjGSAtv7OOfYUIiAr2j","tagline":null,"urlname":"/investor_page/kreos-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKH-64UKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0LnG2CCObUVmSXI2lT92Ch9a8fiTBxFqowuIbkCVG0DPDXf7uc05NA","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$rMGVDhVjpS6PRtxsVudsf1xQNl7qCOcmiUBbjGSAtv7OOfYUIiAr2j","leadcaption":"Lead&nbsp;","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":12000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEyOf6CQw","date":"Feb 2017","amount":"$30M","source":"https://www.massdevice.com/motus-gi-raises-30m-pure-vu-colonoscopy-system/","eventtype":"FundingRoundEvent","investment":[{"name":"Ascent Biomedical Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/ascent-biomedical-ventures","logokey":"$R82UOZRDEyNj11omTifywZ0ewY2onFCh3A75M3GrCJ6fN0mYS8NKz0","tagline":"","urlname":"/investor_page/ascent-biomedical-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkmqncCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"311ec2e8-89b5-42a2-a236-7f2d6d32bd40","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$R82UOZRDEyNj11omTifywZ0ewY2onFCh3A75M3GrCJ6fN0mYS8NKz0","leadcaption":"","followupcaption":""},{"name":"Perceptive Advisors","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/perceptive-advisors","logokey":"$JIoRfOrNs82qw90NI079706rsn7DcxX85uRs7vdsV7xdzkz6WDfUGC","tagline":"","urlname":"/investor_page/perceptive-advisors","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODkwMnkCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8f9beeb3-806e-4ce3-8610-f1822d24b0fc","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JIoRfOrNs82qw90NI079706rsn7DcxX85uRs7vdsV7xdzkz6WDfUGC","leadcaption":"","followupcaption":""},{"name":"Pura Vida Investments","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/pura-vida-investments","logokey":"$zr7GbV4SuI3rKRMAqfnrYwgAwwReI7qR0fZcPuBDRgY1o8Tx1sFfkL","tagline":"","urlname":"/investor_page/pura-vida-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk2uqXCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"956ad2fb-b40b-4060-aed8-ac79c6aba179","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$zr7GbV4SuI3rKRMAqfnrYwgAwwReI7qR0fZcPuBDRgY1o8Tx1sFfkL","leadcaption":"","followupcaption":""},{"name":"Jacobs Investment Company","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/jacobs-investment-company","logokey":null,"tagline":"","urlname":"/investor_page/jacobs-investment-company","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODE1c7HCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"98db2c5b-eca9-45d2-849a-106739ff94c8","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Orchestra Medical Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/orchestra-medical-ventures","logokey":"$rdrHQ11Abn8hYgUXt8rIKFuASZQZkKV1dURdrFMX47ev1eSeWupQIS","tagline":"","urlname":"/investor_page/orchestra-medical-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk2uqXCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"cb060120-50d8-4181-a485-2e14db4994d5","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$rdrHQ11Abn8hYgUXt8rIKFuASZQZkKV1dURdrFMX47ev1eSeWupQIS","leadcaption":"","followupcaption":""},{"name":"SternAegis Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/sternaegis-ventures","logokey":"$c72MUZoNAnhahMreGq8lbUCOwVHXbIiwl596VDkXESOh5bsC5WiTLs","tagline":"","urlname":"/investor_page/sternaegis-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCko46TCww","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"f73f5731-c8e3-41e8-9b07-ce852c425172","fundingsubtype":"Corporate VC","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$c72MUZoNAnhahMreGq8lbUCOwVHXbIiwl596VDkXESOh5bsC5WiTLs","leadcaption":"","followupcaption":""},{"name":"GJG Life Sciences","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/gjg-life-sciences","logokey":null,"tagline":"","urlname":"/investor_page/gjg-life-sciences","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODkwMnECgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"fb39c524-8120-449b-b3dc-02339b6c308b","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":30000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCE7s-xCgw","date":"Sep 2011","amount":"$13.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"96111c34-63bd-440b-82cc-fdd0053309ec","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":13500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}